Mats Karlsson

Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses

Karlsson, Mats O.; Brundavanam, Divya

Ingår i Clinical Pharmacology and Therapeutics, s. 703-712, 2026

• DOI för Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses
• Ladda ner fulltext (pdf) av Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Centanni, Maddalena; Nanou, Afroditi; Terstappen, Leon W. M. M.; Punt, Kees J. A. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 403-413, 2026

• DOI för Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer
• Ladda ner fulltext (pdf) av Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, 2026

• DOI för Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Ladda ner fulltext (pdf) av Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study

Fragoulakis, Vasileios; Swen, Jesse J.; Koufaki, Margarita-Joanna; Blagec, Kathrin et al.

Ingår i eClinicalMedicine, 2026

• DOI för Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study
• Ladda ner fulltext (pdf) av Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study

Response to "Enhance Multistate Models With Clinically Meaningful Graphs"

Ibrahim, Moustafa M. A.; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i CPT, s. 1899-1899, 2025

• DOI för Response to "Enhance Multistate Models With Clinically Meaningful Graphs"
• Ladda ner fulltext (pdf) av Response to "Enhance Multistate Models With Clinically Meaningful Graphs"

Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses

Karlsson, Mats O.; Brundavanam, Divya

Ingår i Clinical Pharmacology and Therapeutics, s. 703-712, 2026

• DOI för Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses
• Ladda ner fulltext (pdf) av Addressing Causality and Homogeneity Assumptions in Exposure-Response Analyses

Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Centanni, Maddalena; Nanou, Afroditi; Terstappen, Leon W. M. M.; Punt, Kees J. A. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 403-413, 2026

• DOI för Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer
• Ladda ner fulltext (pdf) av Longitudinal Analysis of Manually and Automatically Classified Circulating Tumor Biomarkers and their Prediction of Survival in Metastatic Colorectal Cancer

Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Mazariegos Herrera, Andres; Karlsson, Mats O.; Svensson, Elin M.; Dorlo, Thomas P. C.

Ingår i Journal of Antimicrobial Chemotherapy, 2026

• DOI för Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
• Ladda ner fulltext (pdf) av Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis

Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study

Fragoulakis, Vasileios; Swen, Jesse J.; Koufaki, Margarita-Joanna; Blagec, Kathrin et al.

Ingår i eClinicalMedicine, 2026

• DOI för Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study
• Ladda ner fulltext (pdf) av Multinational cost-utility analysis of panel-based pharmacogenetics-guided treatment of patients enrolled in the U-PGx PREPARE study

Response to "Enhance Multistate Models With Clinically Meaningful Graphs"

Ibrahim, Moustafa M. A.; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i CPT, s. 1899-1899, 2025

• DOI för Response to "Enhance Multistate Models With Clinically Meaningful Graphs"
• Ladda ner fulltext (pdf) av Response to "Enhance Multistate Models With Clinically Meaningful Graphs"

Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study

Dam, Merete; Centanni, Maddalena; Centanni, Daniel; Friberg, Lena E. et al.

Ingår i British Journal of Haematology, s. 1920-1929, 2025

• DOI för Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study
• Ladda ner fulltext (pdf) av Early prediction of subsequent peg-asparaginase inactivation in acute lymphoblastic leukaemia patients-A NOPHO ALL2008 study

Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Janssen, Saskia; Vongjarudech, Thanakorn; Karlsson, Mats O.; Upton, Caryn M. et al.

Ingår i Clinical Pharmacokinetics, s. 1885-1896, 2025

• DOI för Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy
• Ladda ner fulltext (pdf) av Bridging to Paediatric Dosing: Relative Bioavailability of Suspended Rifapentine and Isoniazid in an Open-Label Randomized Trial in Adults on Tuberculosis Preventive Therapy

Integrated Modeling of Digital-Motor and Clinician-Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases

Hamdan, Alzahra; Traschütz, Andreas; Beichert, Lukas; Chen, Xiaomei et al.

Ingår i CPT, s. 1857-1868, 2025

• DOI för Integrated Modeling of Digital-Motor and Clinician-Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases
• Ladda ner fulltext (pdf) av Integrated Modeling of Digital-Motor and Clinician-Reported Outcomes Using Item Response Theory: Towards Powerful Trials for Rare Neurological Diseases

Predictors of Ability to Work in Multiple Sclerosis

Wellhagen, Gustaf; Ueckert, Sebastian; Nielsen, Elisabet I.; Smith, Carl et al.

Ingår i CPT, s. 2244-2251, 2025

• DOI för Predictors of Ability to Work in Multiple Sclerosis
• Ladda ner fulltext (pdf) av Predictors of Ability to Work in Multiple Sclerosis

Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy

Centanni, Maddalena; Nijhuis, Janine; Karlsson, Mats O.; Friberg, Lena E.

Ingår i PharmacoEconomics (Auckland), s. 31-43, 2025

• DOI för Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy
• Ladda ner fulltext (pdf) av Comparative Analysis of Traditional and Pharmacometric-Based Pharmacoeconomic Modeling in the Cost-Utility Evaluation of Sunitinib Therapy

Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study

Guchelaar, Henk-Jan; van der Wouden, Cathelijne H.; Manson, Lisanne E. N.; Abdullah-Koolmees, Heshu et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 803-812, 2025

• DOI för Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study
• Ladda ner fulltext (pdf) av Pharmacogenetic Implementation Studies-Lessons Learned From the PREPARE Study

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders

Ryeznik, Yevgen; Hilgers, Ralf-Dieter; Heussen, Nicole; Comets, Emmanuelle et al.

Ingår i CPT, s. 1705-1714, 2025

• DOI för A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders
• Ladda ner fulltext (pdf) av A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders

Competing Risks Analysis of the Finnish Diabetes Prevention Study

Ibrahim, Moustafa M. A.; Uusitupa, Matti; Tuomilehto, Jaakko; Lindström, Jaana et al.

Ingår i CPT, s. 1459-1469, 2025

• DOI för Competing Risks Analysis of the Finnish Diabetes Prevention Study
• Ladda ner fulltext (pdf) av Competing Risks Analysis of the Finnish Diabetes Prevention Study

A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Zou, Yuanxi; Nedelman, Jerry; Karlsson, Mats O.; Svensson, Elin M.

Ingår i Clinical Pharmacokinetics, s. 1357-1365, 2025

• DOI för A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection
• Ladda ner fulltext (pdf) av A Novel Approach to Evaluating the Design of Pediatric Pharmacokinetic Studies Focused on Accurate Dose Selection

Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation

Maravelia, Panagiota; Yao, Haidong; Cai, Curtis; Silva, Daniela Nascimento et al.

Ingår i Gut, s. 1125-1136, 2025

• DOI för Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation
• Ladda ner fulltext (pdf) av Unlocking novel T cell-based immunotherapy for hepatocellular carcinoma through neoantigen-driven T cell receptor isolation

Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit

Arrington, Leticia; van Dijkman, Sven C; Plan, Elodie L.; Karlsson, Mats O.

Ingår i CPT, s. 881-890, 2025

• DOI för Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit
• Ladda ner fulltext (pdf) av Item Response Modeling and Artificial Neural Network for Differentiation of Parkinson's Patients and Subjects Without Evidence of Dopaminergic Deficit

Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Karlsson, Mats O. et al.

Ingår i CPT, s. 1252-1261, 2025

• DOI för Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
• Ladda ner fulltext (pdf) av Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 1292-1302, 2025

• DOI för Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Ladda ner fulltext (pdf) av Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score

Hendrickx, Niels; Mentré, France; Hamdan, Alzahra; Karlsson, Mats O. et al.

Ingår i BMC Medical Research Methodology, 2025

• DOI för Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score
• Ladda ner fulltext (pdf) av Comparing randomized trial designs to estimate treatment effect in rare diseases with longitudinal models: a simulation study showcased by Autosomal Recessive Cerebellar Ataxias using the SARA score

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Palmer, Megan; Zou, Yuanxi; Hesseling, Anneke C.; van der Laan, Louvina et al.

Ingår i British Journal of Clinical Pharmacology, s. 1853-1864, 2025

• DOI för Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
• Ladda ner fulltext (pdf) av Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.

Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, s. 1516-1532, 2025

• DOI för In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.
• Ladda ner fulltext (pdf) av In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Dooley, Kelly E. et al.

Ingår i International Journal of Antimicrobial Agents, 2025

• DOI för Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
• Ladda ner fulltext (pdf) av Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

Haem, Elham; Karlsson, Mats O.; Ueckert, Sebastian

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2025

• DOI för Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials
• Ladda ner fulltext (pdf) av Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Lin, Yu-Jou; Zou, Yuanxi; Karlsson, Mats O.; Svensson, Elin

Ingår i Journal of Antimicrobial Chemotherapy, s. 2561-2569, 2024

• DOI för A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

Gewily, Mohamed; Plan, Elodie L.; Yousefi, Elham; König, Franz et al.

Ingår i Movement Disorders, 2024

• DOI för Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory
• Ladda ner fulltext (pdf) av Quantitative Comparisons of Progressive Supranuclear Palsy Rating Scale Versions Using Item Response Theory

Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Arrington, Leticia; Karlsson, Mats

Ingår i AAPS Journal, 2024

• DOI för Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models
• Ladda ner fulltext (pdf) av Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models

Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Dam, Merete; Centanni, Maddalena; Friberg, Lena E.; Centanni, Daniel et al.

Ingår i Leukemia, s. 712-719, 2024

• DOI för Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia
• Ladda ner fulltext (pdf) av Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

Bjugård Nyberg, Henrik; Chen, Xiaomei; Donnelly, Mark; Fang, Lanyan et al.

Ingår i CPT, s. 1748-1761, 2024

• DOI för Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods
• Ladda ner fulltext (pdf) av Evaluation of model-integrated evidence approaches for pharmacokinetic bioequivalence studies using model averaging methods

A fully automatic tool for development of population pharmacokinetic models

Chen, Xiaomei; Nordgren, Rikard; Belin, Stella; Hamdan, Alzahra et al.

Ingår i CPT, s. 1784-1797, 2024

• DOI för A fully automatic tool for development of population pharmacokinetic models
• Ladda ner fulltext (pdf) av A fully automatic tool for development of population pharmacokinetic models

Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory

Hamdan, Alzahra; Hendrickx, Niels; Hooker, Andrew C.; Chen, Xiaomei et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 1593-1605, 2024

• DOI för Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory
• Ladda ner fulltext (pdf) av Longitudinal Analysis of Natural History Progression of Rare and Ultra‐Rare Cerebellar Ataxias Using Item Response Theory

Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

Chen, Xiaomei; Bjugård Nyberg, Henrik; Donnelly, Mark; Zhao, Liang et al.

Ingår i CPT, s. 1734-1747, 2024

• DOI för Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points
• Ladda ner fulltext (pdf) av Development and comparison of model-integrated evidence approaches for bioequivalence studies with pharmacokinetic end points

Efficiency of multivariate tests in trials in progressive supranuclear palsy

Yousefi, Elham; Gewily, Mohamed; Koenig, Franz; Hoeglinger, Guenter et al.

Ingår i Scientific Reports, 2024

• DOI för Efficiency of multivariate tests in trials in progressive supranuclear palsy
• Ladda ner fulltext (pdf) av Efficiency of multivariate tests in trials in progressive supranuclear palsy

Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea

Wellhagen, Gustaf; Karlsson, Mats O.; Kjellsson, Maria C.; Garmann, Dirk et al.

Ingår i CPT, s. 880-890, 2024

• DOI för Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea
• Ladda ner fulltext (pdf) av Item response theory analysis of daytime sleepiness as a symptom of obstructive sleep apnea

Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias

Hamdan, Alzahra; Hooker, Andrew C.; Chen, Xiaomei; Traschütz, Andreas et al.

Ingår i CPT, s. 1327-1340, 2024

• DOI för Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias
• Ladda ner fulltext (pdf) av Item performance of the scale for the assessment and rating of ataxia in rare and ultra-rare genetic ataxias

Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework

Centanni, Maddalena; Reijnhout, Niels; Thijs, Abel; Karlsson, Mats O. et al.

Ingår i Clinical Pharmacokinetics, s. 871-884, 2024

• DOI för Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework
• Ladda ner fulltext (pdf) av Pharmacogenetic testing or Therapeutic Drug Monitoring: A Quantitative Framework

Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Centanni, Maddalena; Zaher, Omar; Elhad, David; Karlsson, Mats O. et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 297-310, 2024

• DOI för Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children
• Ladda ner fulltext (pdf) av Physiologically-based pharmacokinetic models versus allometric scaling for prediction of tyrosine-kinase inhibitor exposure from adults to children

Evaluation of covariate effects in item response theory models

Wellhagen, Gustaf; Yassen, Ashraf; Garmann, Dirk; Broeker, Astrid et al.

Ingår i CPT, s. 812-822, 2024

• DOI för Evaluation of covariate effects in item response theory models
• Ladda ner fulltext (pdf) av Evaluation of covariate effects in item response theory models

Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis

Thorsted, Anders; Zecchin, Chiara; Berges, Alienor; Karlsson, Mats O. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 703-715, 2024

• DOI för Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis
• Ladda ner fulltext (pdf) av Predicting the Long-Term Effects of Therapeutic Neutralization of Oncostatin M on Human Hematopoiesis

Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

Centanni, Maddalena; van de Velde, Mirjam E.; Uittenboogaard, Aniek; Kaspers, Gertjan J. L. et al.

Ingår i Clinical Pharmacokinetics, s. 197-209, 2024

• DOI för Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis
• Ladda ner fulltext (pdf) av Model-Informed Precision Dosing to Reduce Vincristine-Induced Peripheral Neuropathy in Pediatric Patients: A Pharmacokinetic and Pharmacodynamic Modeling and Simulation Analysis

Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

Brekkan, Ari; Lledo-Garcia, Rocio; Lacroix, Brigitte; Jonsson, Siv et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 65-75, 2024

• DOI för Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach
• Ladda ner fulltext (pdf) av Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach

Properties of the full random-effect modeling approach with missing covariate data

Nyberg, Joakim; Jonsson, E. Niclas; Karlsson, Mats O.; Häggström, Jonas

Ingår i Statistics in Medicine, s. 935-952, 2024

• DOI för Properties of the full random-effect modeling approach with missing covariate data
• Ladda ner fulltext (pdf) av Properties of the full random-effect modeling approach with missing covariate data

A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer

Liu, Han; Milenković‐Grišić, Ana‐Marija; Krishnan, Sreenath M.; Jönsson, Siv et al.

Ingår i CPT, s. 1738-1750, 2023

• DOI för A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer
• Ladda ner fulltext (pdf) av A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non‐small cell lung cancer

A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.

Liu, Han; Milenković-Grišić, Ana-Marija; Madathil Krishnan, Sreenath; Jönsson, Siv et al.

Ingår i CPT, s. 1738-1750, 2023

• DOI för A multistate modeling and simulation framework to learn dose-response of oncology drugs: Application to bintrafusp alfa in non-small cell lung cancer.

Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models

Ibrahim, Eman; Karlsson, Mats; Friberg, Lena

Ingår i CPT, s. 1305-1318, 2023

• DOI för Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models
• Ladda ner fulltext (pdf) av Assessment of ibrutinib scheduling on leukocyte, lymph node size and blood pressure dynamics in chronic lymphocytic leukemia through pharmacokinetic-pharmacodynamic models

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Bukkems, Laura H.; Versloot, Olav; Cnossen, Marjon H.; Jönsson, Siv et al.

Ingår i Thrombosis and Haemostasis, s. 317-325, 2023

• DOI för Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
• Ladda ner fulltext (pdf) av Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A

Training the next generation of pharmacometric modelers: a multisector perspective

Bonate, Peter L.; Barrett, Jeffrey S.; Ait-Oudhia, Sihem; Brundage, Richard et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 5-31, 2023

• DOI för Training the next generation of pharmacometric modelers: a multisector perspective

Generation and application of avatars in pharmacometric modelling

Chasseloup, Estelle; Hooker, Andrew; Karlsson, Mats

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 411-423, 2023

• DOI för Generation and application of avatars in pharmacometric modelling
• Ladda ner fulltext (pdf) av Generation and application of avatars in pharmacometric modelling

Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect

Chasseloup, Estelle; Karlsson, Mats

Ingår i Pharmaceutics, 2023

• DOI för Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect
• Ladda ner fulltext (pdf) av Comparison of Seven Non-Linear Mixed Effect Model-Based Approaches to Test for Treatment Effect

Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine

Chen, Po-Wei; Karlsson, Mats O.; Ueckert, Sebastian; Pritchard-Bell, Ari et al.

Ingår i CPT, s. 1988-2000, 2023

• DOI för Evaluation of the effect of erenumab on migraine-specific questionnaire in patients with chronic and episodic migraine

Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

Centanni, Maddalena; Thijs, Abel; Desar, Ingrid; Karlsson, Mats O. et al.

Ingår i Clinical and Translational Science, s. 73-84, 2023

• DOI för Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors
• Ladda ner fulltext (pdf) av Optimization of blood pressure measurement practices for pharmacodynamic analyses of tyrosine-kinase inhibitors

How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials?

Verbeeck, Johan; Geroldinger, Martin; Thiel, Konstantin; Hooker, Andrew Craig et al.

Ingår i Biometrics, s. 3998-4011, 2023

• DOI för How to Analyze Continuous and Discrete Repeated Measures in Small-Sample Cross-Over Trials?

Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 297-314, 2023

• DOI för Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials
• Ladda ner fulltext (pdf) av Joint longitudinal model-based meta-analysis of FEV₁ and exacerbation rate in randomized COPD trials

Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis

Bukkems, Laura; Jönsson, Siv; Cnossen, Marjon O.; Karlsson, Mats et al.

Ingår i CPT, s. 706-718, 2023

• DOI för Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis
• Ladda ner fulltext (pdf) av Relationship between factor VIII levels and bleeding for rFVIII-SingleChain in severe hemophilia A: A repeated time-to-event analysis

Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

Madathil Krishnan, Sreenath; Friberg, Lena; Mercier, Francois; Zhang, Rong et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 851-858, 2023

• DOI för Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study
• Ladda ner fulltext (pdf) av Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Swen, JesseJ; van der Wouden, Cathelijne H.; Manson, Lisanne E. N.; Abdullah-Koolmees, Heshu et al.

Ingår i The Lancet, s. 347-356, 2023

• DOI för A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Zou, Yuanxi; Nedelman, Jerry; Lombardi, Antonio; Pappas, Frances et al.

Ingår i Clinical Pharmacokinetics, s. 1585-1593, 2022

• DOI för Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
• Ladda ner fulltext (pdf) av Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Grisic, Ana-Marija; Xiong, Wenyuan; Tanneau, Lénaïg; Jönsson, Siv et al.

Ingår i Clinical Cancer Research, s. 1363-1371, 2022

• DOI för Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab
• Ladda ner fulltext (pdf) av Model-Based Characterization of the Bidirectional Interaction Between Pharmacokinetics and Tumor Growth Dynamics in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Tanneau, Lénaïg; Karlsson, Mats; Diacon, Andreas H; Shenje, Justin et al.

Ingår i Clinical Pharmacokinetics, s. 1177-1185, 2022

• DOI för Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
• Ladda ner fulltext (pdf) av Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

An introduction of the full random effects model

Yngman, Gunnar; Nyberg, Henrik B.; Nyberg, Joakim; Jonsson, E. Niclas et al.

Ingår i CPT, s. 149-160, 2022

• DOI för An introduction of the full random effects model
• Ladda ner fulltext (pdf) av An introduction of the full random effects model

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Sasaki, Tomohiro; Svensson, Elin; Wang, Xiaofeng; Wang, Yanlin et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2022

• DOI för Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
• Ladda ner fulltext (pdf) av Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L.; Cramer, Yoninah S. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 873-881, 2022

• DOI för Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
• Ladda ner fulltext (pdf) av Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Dreesen, Erwin; Gijsen, Matthias; Elkayal, Omar; Annaert, Pieter et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2479-2488, 2022

• DOI för Ceftriaxone dosing based on the predicted probability of augmented renal clearance in critically ill patients with pneumonia

Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Llanos-Paez, Carolina C.; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Ingår i Pharmaceutical research, s. 1779-1787, 2022

• DOI för Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients
• Ladda ner fulltext (pdf) av Improved Confidence in a Confirmatory Stage by Application of Item-Based Pharmacometrics Model: Illustration with a Phase III Active Comparator-Controlled Trial in COPD Patients

Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Lyauk, Yassine Kamal; Jonker, Daniel M.; Hooker, Andrew; Lund, Trine Meldgaard et al.

Ingår i AAPS Journal, 2021

• DOI för Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia
• Ladda ner fulltext (pdf) av Bounded Integer Modeling of Symptom Scales Specific to Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Karlsson, Mats O.; Westin, Ake et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 416-423, 2021

• DOI för A Time-to-Event Model Relating Integrated Craving to Risk of Smoking Relapse Across Different Nicotine Replacement Therapy Formulations

Improved numerical stability for the bounded integer model

Ueckert, Sebastian; Karlsson, Mats

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 241-251, 2021

• DOI för Improved numerical stability for the bounded integer model
• Ladda ner fulltext (pdf) av Improved numerical stability for the bounded integer model

Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Minichmayr, Iris K.; Karlsson, Mats O.; Jönsson, Siv

Ingår i Pharmaceutical research, s. 593-605, 2021

• DOI för Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety
• Ladda ner fulltext (pdf) av Pharmacometrics-Based Considerations for the Design of a Pharmacogenomic Clinical Trial Assessing Irinotecan Safety

Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data

Wellhagen, Gustaf J.; Karlsson, Mats O.; Kjellsson, Maria C.

Ingår i AAPS Journal, 2021

• DOI för Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data
• Ladda ner fulltext (pdf) av Comparison of Precision and Accuracy of Five Methods to Analyse Total Score Data

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Tanneau, Lénaïg; Svensson, Elin; Rossenu, Stefaan; Karlsson, Mats

Ingår i CPT, s. 1538-1549, 2021

• DOI för Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
• Ladda ner fulltext (pdf) av Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Svensson, Robin J.; Ribbing, Jakob; Kotani, Naoki; Dolton, Michael et al.

Ingår i CPT, s. 1221-1235, 2021

• DOI för Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires
• Ladda ner fulltext (pdf) av Population repeated time-to-event analysis of exacerbations in asthma patients: A novel approach for predicting asthma exacerbations based on biomarkers, spirometry, and diaries/questionnaires

Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

Krishnan, Sreenath M.; Friberg, Lena E.; Bruno, René; Beyer, Ulrich et al.

Ingår i CPT, s. 1255-1266, 2021

• DOI för Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel
• Ladda ner fulltext (pdf) av Multistate model for pharmacometric analyses of overall survival in HER2-negative breast cancer patients treated with docetaxel

Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models

Chen, Chao; Jönsson, Siv; Yang, Shuying; Plan, Elodie L. et al.

Ingår i CPT, s. 309-317, 2021

• DOI för Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models
• Ladda ner fulltext (pdf) av Detecting placebo and drug effects on Parkinson's disease symptoms by longitudinal item-score models

A general model for cell death and biomarker release from injured tissues

Li, Jingyun; Karlsson, Mats; Sanhajariya, Suchaya; Isbister, Geoffrey K. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 69-82, 2021

• DOI för A general model for cell death and biomarker release from injured tissues

Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial

Llanos-Paez, Carolina; Ambery, Claire; Yang, Shuying; Tabberer, Maggie et al.

Ingår i AAPS Journal, 2021

• DOI för Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial
• Ladda ner fulltext (pdf) av Improved Decision-Making Confidence Using Item-Based Pharmacometric Model: Illustration with a Phase II Placebo-Controlled Trial

Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments

Chasseloup, Estelle; Tessier, Adrien; Karlsson, Mats

Ingår i AAPS Journal, 2021

• DOI för Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments
• Ladda ner fulltext (pdf) av Assessing Treatment Effects with Pharmacometric Models: A New Method that Addresses Problems with Standard Assessments

An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales

Wellhagen, Gustaf; Ueckert, Sebastian; Kjellsson, Maria C.; Karlsson, Mats

Ingår i AAPS Journal, 2021

• DOI för An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales
• Ladda ner fulltext (pdf) av An Item Response Theory-Informed Strategy to Model Total Score Data from Composite Scales

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Garcia-Prats, Anthony J.; Svensson, Elin; Winckler, Jana; Draper, Heather R. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3237-3246, 2021

• DOI för Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

Sharan, Satish; Fang, Lanyan; Lukacova, Viera; Chen, Xiaomei et al.

Ingår i Clinical Pharmacology in Drug Development, s. 220-228, 2021

• DOI för Model-Informed Drug Development for Long-Acting Injectable Products: Summary of American College of Clinical Pharmacology Symposium

Performance of longitudinal item response theory models in shortened or partial assessments.

Arrington, Leticia; Ueckert, Sebastian; Ahamadi, Malidi; Macha, Sreeraj et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 461-471, 2020

• DOI för Performance of longitudinal item response theory models in shortened or partial assessments.
• Ladda ner fulltext (pdf) av Performance of longitudinal item response theory models in shortened or partial assessments.

Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Lyauk, Yassine Kamal; Jonker, Daniel M.; Lund, Trine Meldgaard; Hooker, Andrew et al.

Ingår i AAPS Journal, 2020

• DOI för Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia
• Ladda ner fulltext (pdf) av Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia

Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Tanneau, Lénaïg; Karlsson, Mats O.; Svensson, Elin

Ingår i British Journal of Clinical Pharmacology, s. 913-922, 2020

• DOI för Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis
• Ladda ner fulltext (pdf) av Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

Chasseloup, Estelle; Yngman, Gunnar; Karlsson, Mats

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 485-492, 2020

• DOI för Comparison of covariate selection methods with correlated covariates: prior information versus data information, or a mixture of both?

Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

Netterberg, Ida; Karlsson, Mats; Terstappen, Leon W. M. M.; Koopman, Miriam et al.

Ingår i Clinical Cancer Research, s. 4892-4900, 2020

• DOI för Comparing Circulating Tumor Cell Counts with Dynamic Tumor Size Changes as Predictor of Overall Survival: A Quantitative Modeling Framework

A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism

Haem, Elham; Doostfatemeh, Marziyeh; Firouzabadi, Negar; Ghazanfari, Nima et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 241-253, 2020

• DOI för A longitudinal item response model for Aberrant Behavior Checklist (ABC) data from children with autism

Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

van der Wouden, Cathelijne H.; Bohringer, Stefan; Cecchin, Erika; Cheung, Ka-Chun et al.

Ingår i Pharmacogenetics & Genomics, s. 131-144, 2020

• DOI för Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study
• Ladda ner fulltext (pdf) av Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Abrantes, João A.; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Ingår i Haematologica, s. 1443-1453, 2020

• DOI för Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients
• Ladda ner fulltext (pdf) av Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients

Arshad, Usman; Ploylearmsaeng, Su-arpa; Karlsson, Mats; Doroshyenko, Oxana et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 711-722, 2020

• DOI för Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients
• Ladda ner fulltext (pdf) av Prediction of exposure-driven myelotoxicity of continuous infusion 5-fluorouracil by a semi-physiological pharmacokinetic-pharmacodynamic model in gastrointestinal cancer patients

Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations

Germovsek, Eva; Hansson, Anna; Kjellsson, Maria C.; Perez Ruixo, Juan Jose et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 238-245, 2020

• DOI för Relating Nicotine Plasma Concentration to Momentary Craving Across Four Nicotine Replacement Therapy Formulations

The effect of food on the pharmacokinetics of oral ivermectin

Duthaler, Urs; Leisegang, Rory; Karlsson, Mats; Krähenbühl, Stephan et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 438-440, 2020

• DOI för The effect of food on the pharmacokinetics of oral ivermectin

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

Thorsted, Anders; Bouchene, Salim; Tano, Eva; Castegren, Markus et al.

Ingår i PLOS ONE, 2019

• DOI för A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6
• Ladda ner fulltext (pdf) av A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Brekkan, Ari; Lopez-Lazaro, Luis; Plan, Elodie L.; Nyberg, Joakim et al.

Ingår i AAPS Journal, 2019

• DOI för Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies
• Ladda ner fulltext (pdf) av Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies

Variability Attribution for Automated Model Building

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i AAPS Journal, 2019

• DOI för Variability Attribution for Automated Model Building
• Ladda ner fulltext (pdf) av Variability Attribution for Automated Model Building

Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment

Ibrahim, Moustafa M. A.; Ueckert, Sebastian; Freiberga, Svetlana; Kjellsson, Maria C. et al.

Ingår i AAPS Journal, 2019

• DOI för Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment
• Ladda ner fulltext (pdf) av Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment

A Bounded Integer Model for Rating and Composite Scale Data

Wellhagen, Gustaf J.; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i AAPS Journal, 2019

• DOI för A Bounded Integer Model for Rating and Composite Scale Data
• Ladda ner fulltext (pdf) av A Bounded Integer Model for Rating and Composite Scale Data

A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients

Germovsek, Eva; Ambery, Claire; Yang, Shuying; Beerahee, Misba et al.

Ingår i AAPS Journal, 2019

• DOI för A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients
• Ladda ner fulltext (pdf) av A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT (R) Daily Diary Data from COPD Patients

Development of visual predictive checks accounting for multimodal parameter distributions in mixture models

Arshad, Usman; Chasseloup, Estelle; Nordgren, Rikard; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 241-250, 2019

• DOI för Development of visual predictive checks accounting for multimodal parameter distributions in mixture models

Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Lippert, Joerg; Burghaus, Rolf; Edginton, Andrea; Frechen, Sebastian et al.

Ingår i CPT, s. 878-882, 2019

• DOI för Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences
• Ladda ner fulltext (pdf) av Open Systems Pharmacology Community-An Open Access, Open Source, Open Science Approach to Modeling and Simulation in Pharmaceutical Sciences

Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib

Niebecker, Ronald; Maas, Hugo; Staab, Alexander; Freiwald, Matthias et al.

Ingår i CPT, s. 230-239, 2019

• DOI för Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib
• Ladda ner fulltext (pdf) av Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib

Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

Abrantes, João A.; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Ingår i CPT, s. 894-903, 2019

• DOI för Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII
• Ladda ner fulltext (pdf) av Bayesian Forecasting Utilizing Bleeding Information to Support Dose Individualization of Factor VIII

Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM

Brekkan, Ari; Jönsson, Siv; Karlsson, Mats O.; Plan, Elodie L.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 591-604, 2019

• DOI för Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM
• Ladda ner fulltext (pdf) av Handling underlying discrete variables with bivariate mixed hidden Markov models in NONMEM

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

Schalkwijk, Stein; ter Heine, Rob; Colbers, Angela; Capparelli, Edmund et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1348-1356, 2019

• DOI för Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales

Gottipati, Gopichand; Berges, Alienor C.; Yang, Shuying; Chen, Chao et al.

Ingår i Pharmaceutical research, 2019

• DOI för Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales
• Ladda ner fulltext (pdf) av Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales

Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI:10.1002/pst.1873

Krause, Andreas; Kloft, Charlotte; Huisinga, Wilhelm; Karlsson, Mats et al.

Ingår i Pharmaceutical statistics, s. 278-281, 2019

• DOI för Comment on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharmaceutical Statistics 17 (5):593-606, Sep/Oct 2018, DOI:10.1002/pst.1873

Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data

Abrantes, João A.; Jönsson, Siv; Karlsson, Mats; Nielsen, Elisabet I.

Ingår i British Journal of Clinical Pharmacology, s. 1326-1336, 2019

• DOI för Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data

The Integrated Glucose Insulin Minimal Model: An improved version

Ibrahim, Moustafa M. A.; Largajolli, Anna; Karlsson, Mats; Kjellsson, Maria C.

Ingår i European Journal of Pharmaceutical Sciences, s. 7-19, 2019

• DOI för The Integrated Glucose Insulin Minimal Model: An improved version

Translation between two models; Application with integrated glucose homeostasis models

Ibrahim, Moustafa M. A.; Largajolli, Anna; Kjellsson, Maria C.; Karlsson, Mats

Ingår i Pharmaceutical research, 2019

• DOI för Translation between two models; Application with integrated glucose homeostasis models
• Ladda ner fulltext (pdf) av Translation between two models; Application with integrated glucose homeostasis models

Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers

Duthaler, Urs; Suenderhauf, Claudia; Karlsson, Mats O; Hussner, Janine et al.

Ingår i British Journal of Clinical Pharmacology, s. 626-633, 2019

• DOI för Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers

Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar

Lohy Das, Jesmin; Kyaw, Myat P.; Nyunt, Myat; Chit, Khin et al.

Ingår i Malaria Journal, 2018

• DOI för Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar
• Ladda ner fulltext (pdf) av Population Pharmacokinetic and Pharmacodynamic Properties of Artesunate in Patients with Artemisinin Resistant Infections in Southern Myanmar

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Brekkan, Ari; Lopez-Lazaro, Luis; Yngman, Gunnar; Plan, Elodie L. et al.

Ingår i AAPS Journal, 2018

• DOI för A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim
• Ladda ner fulltext (pdf) av A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim

Model-Based Residual Post-Processing for Residual Model Identification

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O

Ingår i AAPS Journal, 2018

• DOI för Model-Based Residual Post-Processing for Residual Model Identification
• Ladda ner fulltext (pdf) av Model-Based Residual Post-Processing for Residual Model Identification

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Pierrillas, Philippe B.; Fouliard, Sylvain; Chenel, Marylore; Hooker, Andrew et al.

Ingår i AAPS Journal, 2018

• DOI för Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology
• Ladda ner fulltext (pdf) av Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes

Wellhagen, Gustaf J.; Karlsson, Mats O.; Kjellsson, Maria C.

Ingår i CPT, s. 331-341, 2018

• DOI för Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes

A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat

Bouchene, Salim; Marchand, Sandrine; Couet, William; Friberg, Lena E et al.

Ingår i Basic & Clinical Pharmacology & Toxicology, s. 407-422, 2018

• DOI för A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Netterberg, Ida; Karlsson, Mats O; Nielsen, Elisabet I.; Quartino, Angelica L et al.

Ingår i British Journal of Clinical Pharmacology, s. 490-500, 2018

• DOI för The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans

Guiastrennec, Benjamin; Sonne, David P.; Bergstrand, Martin; Vilsbøll, Tina et al.

Ingår i CPT, s. 603-612, 2018

• DOI för Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans
• Ladda ner fulltext (pdf) av Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in humans

Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

Ibrahim, Moustafa M. A.; Ghadzi, Siti Maisharah Sheikh; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i CPT, s. 432-441, 2018

• DOI för Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests
• Ladda ner fulltext (pdf) av Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests

Pharmacometric analysis of the relationship between absolute lymphocyte count, and expanded disability status scale and relapse rate, efficacy end points, in multiple sclerosis trials

Novakovic, Ana M.; Thorsted, Anders; Schindler, Emilie; Jönsson, Siv et al.

Ingår i Journal of clinical pharmacology, s. 1284-1294, 2018

• DOI för Pharmacometric analysis of the relationship between absolute lymphocyte count, and expanded disability status scale and relapse rate, efficacy end points, in multiple sclerosis trials

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Svensson, Elin; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Ingår i Clinical Pharmacokinetics, s. 591-599, 2018

• DOI för Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
• Ladda ner fulltext (pdf) av Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory

Schindler, Emilie; Friberg, Lena; Lum, Bertram L.; Wang, Bei et al.

Ingår i Pharmaceutical research, 2018

• DOI för A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory
• Ladda ner fulltext (pdf) av A pharmacometric analysis of patient-reported outcomes in breast cancer patients through item response theory

Reduced and optimized trial designs for drugs described by a target mediated drug disposition model

Brekkan, Ari; Jönsson, Siv; Karlsson, Mats O; Hooker, Andrew

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 637-647, 2018

• DOI för Reduced and optimized trial designs for drugs described by a target mediated drug disposition model
• Ladda ner fulltext (pdf) av Reduced and optimized trial designs for drugs described by a target mediated drug disposition model

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications

Guiastrennec, Benjamin; Ramachandran, Geetha; Karlsson, Mats O; Kumar, A.K. Hemanth et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 733-741, 2018

• DOI för Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications
• Ladda ner fulltext (pdf) av Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications

An exposure-response (ER) model relating nicotine plasma concentration to momentary craving across different nicotine replacement therapy (NRT) formulations

Germovsek, Eva; Hansson, Anna; Kjellsson, Maria C.; Ruixo, Juan Jose Perez et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2018

Sample size for detection of drug effect using item level and total score models for Unified Parkinson's Disease Rating Scale data

Jönsson, Siv; Yang, Shuying; Chen, Chao; Plan, Elodie L. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2018

Implicit and efficient handling of missing covariate information using full random effects modelling

Nyberg, Joakim; Karlsson, Mats O; Jonsson, Niclas E.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2018

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Lohy Das, Jesmin; Rulisa, Stephen; de Vries, Peter J.; Mens, Petra F. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2018

• DOI för Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Germovsek, Eva; Lutsar, Irja; Kipper, Karin; Karlsson, Mats O et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1908-1916, 2018

• DOI för Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies
• Ladda ner fulltext (pdf) av Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

Baverel, Paul G.; White, Nicholas; Vicini, Paolo; Karlsson, Mats O et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 826-835, 2018

• DOI för Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma

A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption

Back, Hyun-moon; Song, Byungjeong; Pradhan, Sudeep; Chae, Jung-woo et al.

Ingår i BMC Pharmacology & Toxicology, 2018

• DOI för A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption

Model Description Language (MDL): A Standard for Modeling and Simulation

Smith, Mike K.; Moodie, Stuart L.; Bizzotto, Roberto; Blaudez, Eric et al.

Ingår i CPT, s. 647-650, 2017

• DOI för Model Description Language (MDL): A Standard for Modeling and Simulation

A Minimal Continuous-Time Markov Pharmacometric Model.

Schindler, Emilie; Karlsson, Mats O.

Ingår i AAPS Journal, s. 1424-1435, 2017

• DOI för A Minimal Continuous-Time Markov Pharmacometric Model.
• Ladda ner fulltext (pdf) av A Minimal Continuous-Time Markov Pharmacometric Model.

Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis

Novakovic, Ana M.; Krekels, Elke H.J.; Munafo, Alain; Ueckert, Sebastian et al.

Ingår i AAPS Journal, s. 172-179, 2017

• DOI för Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis
• Ladda ner fulltext (pdf) av Application of Item Response Theory to Modeling of Expanded Disability Status Scale in Multiple Sclerosis

Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia

Lohy Das, Jesmin; Dondorp, Arjen M.; Nosten, Francois; Aung, Pyae Phyo et al.

Ingår i AAPS Journal, s. 1842-1854, 2017

• DOI för Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia
• Ladda ner fulltext (pdf) av Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia

Modeling a Composite Score in Parkinson's Disease Using Item Response Theory

Gottipati, Gopichand; Karlsson, Mats O.; Plan, Elodie L.

Ingår i AAPS Journal, s. 837-845, 2017

• DOI för Modeling a Composite Score in Parkinson's Disease Using Item Response Theory
• Ladda ner fulltext (pdf) av Modeling a Composite Score in Parkinson's Disease Using Item Response Theory

Model averaging for robust assessment of QT prolongation by concentration-response analysis

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O; Renard, Didier et al.

Ingår i Statistics in Medicine, s. 3844-3857, 2017

• DOI för Model averaging for robust assessment of QT prolongation by concentration-response analysis

Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

Nguyen, T. H. T.; Mouksassi, M-S; Holford, N.; Al-Huniti, N. et al.

Ingår i CPT, s. 87-109, 2017

• DOI för Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics
• Ladda ner fulltext (pdf) av Model Evaluation of Continuous Data Pharmacometric Models: Metrics and Graphics

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

Schindler, Emilie; Amantea, Michael A; Karlsson, Mats O; Friberg, Lena E

Ingår i CPT, s. 373-382, 2017

• DOI för A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
• Ladda ner fulltext (pdf) av A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients

Model-Based Interspecies Scaling of Glucose Homeostasis

Alskär, Oskar; Karlsson, Mats O.; Kjellsson, Maria C.

Ingår i CPT, s. 778-786, 2017

• DOI för Model-Based Interspecies Scaling of Glucose Homeostasis
• Ladda ner fulltext (pdf) av Model-Based Interspecies Scaling of Glucose Homeostasis

Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis

Ghadzi, Siti Maisharah Sheikh; Karlsson, Mats O; Kjellsson, Maria C.

Ingår i CPT, s. 686-694, 2017

• DOI för Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia

Krekels, E. H. J.; Novakovic, Ana M.; Vermeulen, A. M.; Friberg, Lena E et al.

Ingår i CPT, s. 543-551, 2017

• DOI för Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia
• Ladda ner fulltext (pdf) av Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia

Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Svensson, Elin M.; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2017

• DOI för Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Netterberg, Ida; Nielsen, Elisabet I.; Friberg, Lena E; Karlsson, Mats O.

Ingår i Cancer Chemotherapy and Pharmacology, s. 343-353, 2017

• DOI för Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring
• Ladda ner fulltext (pdf) av Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Brill, Margreke JE; Svensson, Elin M; Pandie, Mishal; Maartens, Gary et al.

Ingår i International Journal of Antimicrobial Agents, s. 212-217, 2017

• DOI för Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
• Ladda ner fulltext (pdf) av Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Differentiation and prognosis of healthy subjects, swedds and parkinson's patients using a multi-dimensional item response theory model

van Dijkman, Sven; Ueckert, Sebastian; Plan, Elodie L.; Karlsson, Mats O.

Ingår i Journal of the Neurological Sciences, s. 97-98, 2017

• DOI för Differentiation and prognosis of healthy subjects, swedds and parkinson's patients using a multi-dimensional item response theory model

Second order Taylor expansion of likelihood-based models

Aoki, Yasunori; Nyberg, Joakim; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2017

Comparison of diagnostics using model-based post-processing for fast automated model building

Ibrahim, Moustafa M. A.; Nordgren, Rikard; Kjellsson, Maria C.; Karlsson, Mats O

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2017

Differentiation between Parkinson's disease patients and SWEDDs based on the MDS-UPDRS

van Dijkman, Sven; Gottipati, Gopichand; Plan, Elodie L.; Karlsson, Mats O

Ingår i European Journal of Neurology, s. 642-642, 2017

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Svensson, Elin M.; Karlsson, Mats O

Ingår i Journal of Antimicrobial Chemotherapy, s. 3398-3405, 2017

• DOI för Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
• Ladda ner fulltext (pdf) av Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Mathematical modelling of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 following ingestion of glucose

Røge, Rikke Meldgaard; Bagger, Jonatan I.; Alskär, Oskar; Kristensen, Niels R. et al.

Ingår i Basic & Clinical Pharmacology & Toxicology, s. 290-297, 2017

• DOI för Mathematical modelling of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 following ingestion of glucose

Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia

Wuerthwein, Gudrun; Lanvers-Kaminsky, Claudia; Hempel, Georg; Gastine, Silke et al.

Ingår i European journal of drug metabolism and pharmacokinetics, s. 955-963, 2017

• DOI för Population Pharmacokinetics to Model the Time-Varying Clearance of the PEGylated Asparaginase Oncaspar^® in Children with Acute Lymphoblastic Leukemia

An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 509-520, 2017

• DOI för An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty
• Ladda ner fulltext (pdf) av An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Dorlo, Thomas P. C.; Kip, Anke E.; Younis, Brima M.; Ellis, Sally J. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3131-3140, 2017

• DOI för Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study
• Ladda ner fulltext (pdf) av Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

van der Wouden, C. H.; Cambon-Thomsen, A.; Cecchin, E.; Cheung, K. C. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 341-358, 2017

• DOI för Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium

Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models

Haem, Elham; Harling, Kajsa; Ayatollahi, Seyyed Mohammad Taghi; Zare, Najaf et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 55-66, 2017

• DOI för Adjusted adaptive Lasso for covariate model-building in nonlinear mixed-effect pharmacokinetic models

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Sadiq, Muhammad W; Nielsen, Elisabet I.; Khachman, Dalia; Conil, Jean-Marie et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 69-79, 2017

• DOI för A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.
• Ladda ner fulltext (pdf) av A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Population pharmacokinetics of cladribine in patients with multiple sclerosis

Savic, Radojka M.; Novakovic, Ana M.; Ekblom, Marianne; Munafo, Alain et al.

Ingår i Clinical Pharmacokinetics, s. 1245-1253, 2017

• DOI för Population pharmacokinetics of cladribine in patients with multiple sclerosis
• Ladda ner fulltext (pdf) av Population pharmacokinetics of cladribine in patients with multiple sclerosis

An Automated Sampling Importance Resampling Procedure For Estimating Parameter Uncertainty

Dosne, Anne-Gaëlle; Bergstrand, M.; Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, 2017

Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine

Permala, Jesmin; Tarning, Joel; Nosten, François; White, Nicholas J. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2017

• DOI för Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine
• Ladda ner fulltext (pdf) av Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine

Impact of demographics and disease progression on the relationship between glucose and HbA1c

Claussen, Anetta; Möller, Jonas B.; Kristensen, Niels R.; Klim, Sören et al.

Ingår i European Journal of Pharmaceutical Sciences, s. 417-423, 2017

• DOI för Impact of demographics and disease progression on the relationship between glucose and HbA1c

Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Svensson, Elin M.; Acharya, Chayan; Clauson, Björn; Dooley, Kelly E. et al.

Ingår i AAPS Journal, s. 171-179, 2016

• DOI för Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats

Choy, Steve; de Winter, Willem; Karlsson, Mats O.; Kjellsson, Maria C.

Ingår i AAPS Journal, s. 1203-1212, 2016

• DOI för Modeling the Disease Progression from Healthy to Overt Diabetes in ZDSD Rats

A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials

Korell, Julia; Martin, S. W.; Karlsson, Mats O.; Ribbing, Jakob

Ingår i Clinical Pharmacology and Therapeutics, s. 315-324, 2016

• DOI för A Model-Based Longitudinal Meta-Analysis of FEV1 in Randomized COPD Trials

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Hennig, Stefanie; Svensson, Elin M; Niebecker, Ronald; Fourie, P Bernard et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1330-1340, 2016

• DOI för Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Krekels, Elke H. J.; Niebecker, Ronald; Karlsson, Mats O.; Miller, Raymond et al.

Ingår i Clinical Pharmacokinetics, s. 1079-1090, 2016

• DOI för Population Pharmacokinetics of Edoxaban in Patients with Non-Valvular Atrial Fibrillation in the ENGAGE AF-TIMI 48 Study, a Phase III Clinical Trial

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Møller, J B; Kristensen, N R; Klim, S; Karlsson, Mats O. et al.

Ingår i CPT, s. 388-9, 2016

• DOI för Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches.

Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

Guiastrennec, Benjamin; Sonne, D. P.; Hansen, M.; Bagger, J. I. et al.

Ingår i CPT, s. 692-700, 2016

• DOI för Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake
• Ladda ner fulltext (pdf) av Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Svensson, Elin M; Dosne, Anne-Gaëlle; Karlsson, Mats O

Ingår i CPT, s. 682-691, 2016

• DOI för Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin
• Ladda ner fulltext (pdf) av Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Nyberg, Joakim; Karlsson, Kristin E.; Jönsson, Siv; Yin, O. Q. P. et al.

Ingår i CPT, s. 222-232, 2016

• DOI för Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism
• Ladda ner fulltext (pdf) av Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism

Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes

Choy, Steve; Kjellsson, Maria; Karlsson, Mats; de Winter, Willem

Ingår i CPT, s. 11-19, 2016

• DOI för Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes
• Ladda ner fulltext (pdf) av Weight-HbA1c-Insulin-Glucose Model for Describing Disease Progression of Type 2 Diabetes

PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor

Schindler, Emilie; Amantea, M. A.; Karlsson, Mats O.; Friberg, L. E.

Ingår i CPT, s. 173-181, 2016

• DOI för PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor
• Ladda ner fulltext (pdf) av PK-PD Modeling of Individual Lesion FDG-PET Response to Predict Overall Survival in Patients With Sunitinib-treated Gastrointestinal Stromal Tumor

Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes

Alskär, Oskar; Bagger, Jonatan I; Røge, Rikke M; Knop, Filip K et al.

Ingår i Journal of clinical pharmacology, s. 340-348, 2016

• DOI för Semi-mechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes

Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling

Dosne, Anne-Gaëlle; Bergstrand, Martin; Harling, Kajsa; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 583-596, 2016

• DOI för Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling
• Ladda ner fulltext (pdf) av Improving The Estimation Of Parameter Uncertainty Distributions In Nonlinear Mixed Effects Models Using Sampling Importance Resampling

dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap

Dosne, Anne-Gaëlle; Niebecker, Ronald; Karlsson, Mats O.

Ingår i Journal Of Pharmacokinetics And Pharmacodynamics, s. 597-608, 2016

• DOI för dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap
• Ladda ner fulltext (pdf) av dOFV distributions: A New Diagnostic For The Adequacy Of Parameter Uncertainty In Nonlinear Mixed-Effects Models Applied To The Bootstrap

BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

Chae, Jung-woo; Teo, Yi Ling; Ho, Han Kiat; Lee, Jaeyeon et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 623-632, 2016

• DOI för BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen

A proof-of-principle example for identifying drug effect from a mechanistic model with a more parsimonious model

Wang, Shijun; Karlsson, Kristin E.; Kjellsson, Maria; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2016

Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations

Deng, Chenhui; Plan, Elodie L.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 305-314, 2016

• DOI för Approaches for modeling within subject variability in pharmacometric count data analysis: dynamic inter-occasion variability and stochastic differential equations

A strategy for residual error modeling incorporating scedasticity of variance and distribution shape

Dosne, Anne-Gaëlle; Bergstrand, Martin; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 137-151, 2016

• DOI för A strategy for residual error modeling incorporating scedasticity of variance and distribution shape
• Ladda ner fulltext (pdf) av A strategy for residual error modeling incorporating scedasticity of variance and distribution shape

Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Bonate, Peter L.; Ahamadi, Malidi; Budha, Nageshwar; de la Pena, Amparo et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 123-135, 2016

• DOI för Methods and strategies for assessing uncontrolled drug-drug interactions in population pharmacokinetic analyses: results from the International Society of Pharmacometrics (ISOP) Working Group

Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

Henin, Emilie; Bergstrand, Martin; Weitschies, Werner; Karlsson, Mats O.

Ingår i Pharmaceutical research, s. 751-762, 2016

• DOI för Meta-analysis of Magnetic Marker Monitoring Data to Characterize the Movement of Single Unit Dosage Forms Though the Gastrointestinal Tract Under Fed and Fasting Conditions

A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R

Acharya, Chayan; Hooker, Andrew C.; Turkyilmaz, Gulbeyaz Yildiz; Jönsson, Siv et al.

Ingår i Computer Methods and Programs in Biomedicine, s. 83-93, 2016

• DOI för A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R
• Ladda ner fulltext (pdf) av A diagnostic tool for population models using non-compartmental analysis: The ncappc package for R

Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Swat, M. J.; Moodie, S.; Wimalaratne, S. M.; Kristensen, N. R. et al.

Ingår i CPT, s. 316-319, 2015

• DOI för Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development
• Ladda ner fulltext (pdf) av Pharmacometrics Markup Language (PharmML): Opening New Perspectives for Model Exchange in Drug Development

Covariate analysis using item response theory modelling of expanded disability status scale (EDSS): a case study of cladribine tablets

Novakovic, A.; Krekels, E. H. J.; Savic, R.; Munafo, A. et al.

Ingår i Multiple Sclerosis Journal, s. 704-705, 2015

Predicting Reductions in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations from FEV1-A Model-Based Meta-Analysis of Literature Data from Controlled Randomized Clinical Trials

Ribbing, Jakob; Korell, Julia; Cerasoli, Frank; Milligan, Peter A. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions: extending the simplified reference tissue model

Kågedal, Matts; Varnäs, Katarina; Hooker, Andrew C; Karlsson, Mats O

Ingår i British Journal of Clinical Pharmacology, s. 116-127, 2015

• DOI för Estimation of drug receptor occupancy when non-displaceable binding differs between brain regions: extending the simplified reference tissue model

Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Schindler, Emilie; Wang, Bei; Lum, Bert; Girish, Sandhya et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

• DOI för Analyzing Patient-Reported Outcomes in Breast Cancer throughItem-Response Theory Pharmacometric Modeling

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Svensson, Elin M.; Murray, Stephen; Karlsson, Mats O.; Dooley, Kelly E.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1106-1114, 2015

• DOI för Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment

Kågedal, Matts; Karlsson, Mats; Hooker, Andrew C

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 211-224, 2015

• DOI för Improved precision of exposure-response relationships by optimal dose-selection. Examples from studies of receptor occupancy using PET and dose finding for neuropathic pain treatment

Quantitative Model Diagrams (QMD): A New Perspective in Model Evaluation

Guiastrennec, Benjamin; Keizer, Ron J.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Modeling to Inform Optimal Dose of Vorapaxar

Gheyas, Ferdous; Lee, Junghoon; Chain, Anne; Stone, Julie et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

Handling Underlying Discrete Variables with Mixed Hidden Markov Models in NONMEM

Plan, Elodie L.; Nyberg, Joakim; Bauer, Robert J.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2015

Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Niebecker, Ronald; Jönsson, Siv; Karlsson, Mats O; Miller, Raymond et al.

Ingår i British Journal of Clinical Pharmacology, s. 1374-1387, 2015

• DOI för Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study

Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution

Clewe, Oskar; Karlsson, Mats O.; Simonsson, Ulrika S. H.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 699-708, 2015

• DOI för Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution
• Ladda ner fulltext (pdf) av Evaluation of optimized bronchoalveolar lavage sampling designs for characterization of pulmonary drug distribution

Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

Jönsson, Siv; Simonsson, Ulrika S. H.; Miller, Raymond; Karlsson, Mats O.

Ingår i Journal of clinical pharmacology, s. 1268-1279, 2015

• DOI för Population pharmacokinetics of edoxaban and its main metabolite in a dedicated renal impairment study

A mathematical disease progression model for the effect of diet and exercise in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study (FDPS)

Ghadzi, Siti Maisharah Sheikh; Karlsson, Mats O.; de Mello, V. D.; Uusitupa, M. et al.

Ingår i Diabetologia, 2015

Interspecies scaling of dynamic glucose and insulin using a mathematical model approach

Alskar, Oskar; Karlsson, Mats O.; Kjellsson, Maria C.

Ingår i Diabetologia, 2015

Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

Baverel, P.; Karlsson, Mats; Agoram, B.; Kantaria, R.

Ingår i Allergy. European Journal of Allergy and Clinical Immunology, s. 35-35, 2015

• DOI för Characterization of dose-FEV1 response of tralokinumab, an investigational anti-IL13 monoclonal antibody in patients with uncontrolled asthma: a population pharmacokinetic/pharmacodynamic modeling analysis

Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

Quartino, Angelica L.; Karlsson, Mats O.; Lindman, Henrik; Friberg, Lena E.

Ingår i Pharmaceutical research, s. 3390-3403, 2014

• DOI för Characterization of Endogenous G-CSF and the Inverse Correlation to Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Using Population Modeling

Concordance between criteria for covariate model building

Hennig, Stefanie; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 109-125, 2014

• DOI för Concordance between criteria for covariate model building

Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients With Certolizumab Pegol

Lacroix, Brigitte; Karlsson, Mats; Friberg, Lena

Ingår i CPT, s. 1-11, 2014

• DOI för Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients With Certolizumab Pegol

Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Møller, J B; Kristensen, N R; Klim, S; Karlsson, Mats O et al.

Ingår i CPT, 2014

• DOI för Methods for Predicting Diabetes Phase III Efficacy Outcome From Early Data: Superior Performance Obtained Using Longitudinal Approaches

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Svensson, Elin M.; Dooley, Kelly E.; Karlsson, Mats O.

Ingår i Antimicrobial Agents and Chemotherapy, s. 6406-6412, 2014

• DOI för Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention

Bergstrand, Martin; Nosten, Francois; Lwin, Khin Maung; Karlsson, Mats O. et al.

Ingår i Science Translational Medicine, 2014

• DOI för Characterization of an in vivo concentration-effect relationship for piperaquine in malaria chemoprevention

Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Ernest II, Charles; Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 639-654, 2014

• DOI för Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model
• Ladda ner fulltext (pdf) av Optimal clinical trial design based on a dichotomous Markov-chain mixed-effect sleep model

Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Ingår i Pharmaceutical research, s. 2152-2165, 2014

• DOI för Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling
• Ladda ner fulltext (pdf) av Improved Utilization of ADAS-cog Assessment Data through Item Response Theory based Pharmacometric Modeling

Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7

Johansson, Åsa M.; Ueckert, Sebastian; Plan, Elodie L.; Hooker, Andrew C. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 223-238, 2014

• DOI för Evaluation of Bias, Precision, Robustness and Runtime for Estimation Methods in NONMEM 7

Use of a linearization approximation facilitating stochastic model building

Svensson, Elin M.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 153-158, 2014

• DOI för Use of a linearization approximation facilitating stochastic model building
• Ladda ner fulltext (pdf) av Use of a linearization approximation facilitating stochastic model building

A linearization approach for the model-based analysis of combined aggregate and individual patient data

Ravva, Patanjali; Karlsson, Mats O.; French, Jonathan L.

Ingår i Statistics in Medicine, s. 1460-1476, 2014

• DOI för A linearization approach for the model-based analysis of combined aggregate and individual patient data

Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method's Sensitivity to eta-Shrinkage

Johansson, Åsa M.; Karlsson, Mats O.

Ingår i AAPS Journal, s. 1035-1042, 2013

• DOI för Multiple Imputation of Missing Covariates in NONMEM and Evaluation of the Method's Sensitivity to eta-Shrinkage

Comparison of Methods for Handling Missing Covariate Data

Johansson, Åsa M.; Karlsson, Mats O.

Ingår i AAPS Journal, s. 1232-1241, 2013

• DOI för Comparison of Methods for Handling Missing Covariate Data

Optimizing disease progression study designs for drug effect discrimination

Ueckert, Sebastian; Hennig, Stefanie; Nyberg, Joakim; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 587-596, 2013

• DOI för Optimizing disease progression study designs for drug effect discrimination

Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Keizer, Ron J; Karlsson, M O; Hooker, Andrew C

Ingår i CPT, 2013

• DOI för Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose

Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Mentré, F; Chenel, M; Comets, E; Grevel, J et al.

Ingår i CPT, 2013

• DOI för Current Use and Developments Needed for Optimal Design in Pharmacometrics: A Study Performed Among DDMoRe's European Federation of Pharmaceutical Industries and Associations Members

Comparisons of Analysis Methods for Proof-of-Concept Trials

Karlsson, Kristin E; Vong, Camille; Bergstrand, Martin; Jonsson, E Niclas et al.

Ingår i CPT, 2013

• DOI för Comparisons of Analysis Methods for Proof-of-Concept Trials

Whole Body Physiologically-Based Pharmacokinetic Model for Colistin and Colistimethate Sodium (CMS) in Six Different Species: Mouse, Rat, Rabbit, Baboon, Pig and Human

Bouchene, Salim; Marchand, Sandrine; Friberg, Lena E.; Björkman, Sven et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

van der Walt, J-S; Hong, Y; Zhang, L; Pfister, M et al.

Ingår i CPT, 2013

• DOI för A Nonlinear Mixed Effects Pharmacokinetic Model for Dapagliflozin and Dapagliflozin 3-O-glucuronide in Renal or Hepatic Impairment

Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims

Marshall, S F; Hemmings, R; Josephson, F; Karlsson, M O et al.

Ingår i CPT, 2013

• DOI för Modeling and simulation to optimize the design and analysis of confirmatory trials, characterize risk-benefit, and support label claims

Best practices in population modeling should always be evolving

Karlsson, M O; Mentré, F

Ingår i CPT, 2013

• DOI för Best practices in population modeling should always be evolving

Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development

Harnisch, L; Matthews, I; Chard, J; Karlsson, M O

Ingår i CPT, 2013

• DOI för Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

Hansson, E K; Ma, G; Amantea, M A; French, J et al.

Ingår i CPT, 2013

• DOI för PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

Hansson, E K; Amantea, M A; Westwood, P; Milligan, P A et al.

Ingår i CPT, 2013

• DOI för PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST

Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

Møller, J B; Overgaard, R V; Kjellsson, Maria C; Kristensen, N R et al.

Ingår i CPT, 2013

• DOI för Longitudinal Modeling of the Relationship Between Mean Plasma Glucose and HbA1c Following Antidiabetic Treatments

A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region

Kågedal, Matts; Cselenyi, Zsolt; Nyberg, Svante; Raboisson, Patrick et al.

Ingår i NeuroImage, s. 160-169, 2013

• DOI för A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066-Estimating occupancy in the absence of a reference region

Simultaneous optimal experimental design for in vitro binding parameter estimation

Ernest II, Charles Steven; Karlsson, Mats O.; Hooker, Andrew C.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 573-585, 2013

• DOI för Simultaneous optimal experimental design for in vitro binding parameter estimation

Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Choy, Steve; Henin, Emilie; van der Walt, Jan-Stefan; Kjellsson, Maria et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 1-10, 2013

• DOI för Identification of the primary mechanism of action of an insulin secretagogue from meal test data in healthy volunteers based on an integrated glucose-insulin model

Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

Zhang, Chao; Denti, Paolo; Decloedt, Eric H.; Ren, Yuan et al.

Ingår i British Journal of Clinical Pharmacology, s. 741-751, 2013

• DOI för Model-based evaluation of the pharmacokinetic differences between adults and children for lopinavir and ritonavir in combination with rifampicin

A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A

Frobel, Anne-Kristina; Karlsson, Mats O.; Backman, Janne T.; Hoppu, Kalle et al.

Ingår i British Journal of Clinical Pharmacology, s. 603-615, 2013

• DOI för A time-to-event model for acute rejections in paediatric renal transplant recipients treated with ciclosporin A

Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

Di Paolo, Antonello; Tascini, Carlo; Polillo, Marialuisa; Gemignani, Giulia et al.

Ingår i International Journal of Antimicrobial Agents, s. 250-255, 2013

• DOI för Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Svensson, Elin M.; Aweeka, Francesca; Park, Jeong-Gun; Marzan, Florence et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 2780-2787, 2013

• DOI för Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

Kjellsson, Maria C.; Cosson, Valerie F.; Mazer, Norman A.; Frey, Nicolas et al.

Ingår i Journal of clinical pharmacology, s. 589-600, 2013

• DOI för A Model-Based Approach to Predict Longitudinal HbA1c, Using Early Phase Glucose Data From Type 2 Diabetes Mellitus Patients After Anti-Diabetic Treatment

A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Lledó-García, Rocío; Mazer, Norman A.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 129-142, 2013

• DOI för A semi-mechanistic model of the relationship between average glucose and HbA1c in healthy and diabetic subjects

Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

Schneck, Karen B.; Zhang, Xin; Bauer, Robert; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 67-80, 2013

• DOI för Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model

A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

Chigutsa, Emmanuel; Patel, Kashyap; Denti, Paolo; Visser, Marianne et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 789-795, 2013

• DOI för A Time-to-Event Pharmacodynamic Model Describing Treatment Response in Patients with Pulmonary Tuberculosis Using Days to Positivity in Automated Liquid Mycobacterial Culture

Benefits of an Item Response Theory Based Analysis of ADAS-cog Assessments

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

Pharmacometric Modeling of Clinical ADAS-cog Assessment Data using Item Response Theory

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

Predicting Baseline ADAS-cog Scores from Screening Information using Item Response Theory and Full Random Effect Covariate Modeling

Ueckert, Sebastian; Plan, Elodie L.; Ito, Kaori; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

ADOPT (A Dynamic HbA(1c) EndpOint Prediction Tool): A framework for Predicting Primary Endpoint in Phase 3 Diabetes Trials

Moller, Jonas B.; Overgaard, Rune V.; Kjellsson, Maria C.; Kristensen, Niels R. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

A Model Predicting Penetration of Rifampicin from Plasma to Epithelial Lining Fluid and Alveolar Cells

Clewe, Oskar; Karlsson, Mats O.; Goutelle, Sylvain; Conte, John E. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2013

Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models

Plan, Elodie L.; Maloney, Alan; Mentré, France; Karlsson, Mats O. et al.

Ingår i AAPS Journal, s. 420-432, 2012

• DOI för Performance comparison of various maximum likelihood nonlinear mixed-effects estimation methods for dose-response models

Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact

Xu, Xu Steven; Yuan, Min; Karlsson, Mats O.; Dunne, Adrian et al.

Ingår i AAPS Journal, s. 927-936, 2012

• DOI för Shrinkage in Nonlinear Mixed-Effects Population Models: Quantification, Influencing Factors, and Impact

Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

Vong, Camille; Bergstrand, Martin; Nyberg, Joakim; Karlsson, Mats O.

Ingår i AAPS Journal, s. 176-186, 2012

• DOI för Rapid Sample Size Calculations for a Defined Likelihood Ratio Test-Based Power in Mixed-Effects Models

A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

Hénin, Emilie; Bergstrand, Martin; Standing, Joseph F.; Karlsson, Mats O.

Ingår i AAPS Journal, s. 155-163, 2012

• DOI för A mechanism-Based Approach for Absorption Modeling: The Gastro-Intestinal Transit Time (GITT) Model

PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Nyberg, Joakim; Ueckert, Sebastian; Strömberg, Eric; Hennig, Stefanie et al.

Ingår i Computer Methods and Programs in Biomedicine, s. 789-805, 2012

• DOI för PopED: An extended, parallelized, nonlinear mixed effects models optimal design tool

Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

Zhang, Chao; McIlleron, Helen; Ren, Yuan; van der Walt, Jan-Stefan et al.

Ingår i Antiviral Therapy, s. 25-33, 2012

• DOI för Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children

Serial correlation in optimal design for nonlinear mixed effects models

Nyberg, Joakim; Höglund, Richard; Bergstrand, Martin; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 239-249, 2012

• DOI för Serial correlation in optimal design for nonlinear mixed effects models

Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

Zhang, Chao; Denti, Paolo; Decloedt, Eric; Maartens, Gary et al.

Ingår i British Journal of Clinical Pharmacology, s. 758-767, 2012

• DOI för Model-based approach to dose optimization of lopinavir/ritonavir when co-administered with rifampicin

A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations

Bergstrand, Martin; Söderlind, Erik; Eriksson, Ulf G; Weitschies, Werner et al.

Ingår i Pharmaceutical research, s. 695-706, 2012

• DOI för A Semi-mechanistic Modeling Strategy to Link In Vitro and In Vivo Drug Release for Modified Release Formulations

Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Hennig, Stefanie; Nyberg, Joakim; Fanta, Samuel; Backman, Janne T. et al.

Ingår i Journal of clinical pharmacology, s. 347-360, 2012

• DOI för Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin

Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

Kågedal, Matts; Cselényi, Zsolt; Nyberg, Svante; Jönsson, Siv et al.

Ingår i NeuroImage, s. 849-856, 2012

• DOI för Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children

Viljoen, M.; Karlsson, Mats O; Meyers, T. M.; Gous, H. et al.

Ingår i European Journal of Clinical Pharmacology, s. 339-347, 2012

• DOI för Influence of CYP2B6 516G > T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children

Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Lledó-García, Rocío; Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C et al.

Ingår i Journal of clinical pharmacology, s. 29-38, 2012

• DOI för Ethically Attractive Dose-Finding Designs for Drugs With a Narrow Therapeutic Index

Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

Friberg, Lena E.; Ravva, Patanjali; Karlsson, Mats O.; Liu, Ping

Ingår i Antimicrobial Agents and Chemotherapy, s. 3032-3042, 2012

• DOI för Integrated Population Pharmacokinetic Analysis of Voriconazole in Children, Adolescents, and Adults

Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology

Delattre, Maud; Savic, Radojka M.; Miller, Raymond; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 263-271, 2012

• DOI för Analysis of exposure-response of CI-945 in patients with epilepsy: application of novel mixed hidden Markov modeling methodology

Population Pharmacokinetics of Busulfan in Children: Response

Trame, Mirjam N.; Bergstrand, Martin; Karlsson, Mats O.; Hempel, Georg

Ingår i Clinical Cancer Research, s. 2717-2718, 2012

• DOI för Population Pharmacokinetics of Busulfan in Children: Response

Evaluation of IPPSE, an alternative method for sequential population PKPD analysis

Lacroix, Brigitte D.; Friberg, Lena E.; Karlsson, Mats O

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 177-193, 2012

• DOI för Evaluation of IPPSE, an alternative method for sequential population PKPD analysis

A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations

Bergstrand, Martin; Söderlind, Erik; Eriksson, Ulf G; Weitschies, Werner et al.

Ingår i Pharmaceutical research, s. 574-584, 2012

• DOI för A semi-mechanistic modeling strategy for characterization of regional absorption properties and prospective prediction of plasma concentrations following administration of new modified release formulations

Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus

Hamrén, Bengt; Öhman, K Peter; Svensson, Maria K; Karlsson, Mats O.

Ingår i Journal of clinical pharmacology, s. 1317-1327, 2012

• DOI för Pharmacokinetic-Pharmacodynamic Assessment of the Interrelationships Between Tesaglitazar Exposure and Renal Function in Patients With Type 2 Diabetes Mellitus

Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model

Jauslin, Petra; Karlsson, Mats O; Frey, Nicolas

Ingår i Journal of clinical pharmacology, s. 1861-1871, 2012

• DOI för Identification of the Mechanism of Action of a Glucokinase Activator From Oral Glucose Tolerance Test Data in Type 2 Diabetic Patients Based on an Integrated Glucose-Insulin Model

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Quartino, Angelica; Friberg, Lena E; Karlsson, Mats O

Ingår i Investigational new drugs, s. 833-845, 2012

• DOI för A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

Likert Pain Scores Modeling: A Markov Integer Model and an Autoregressive Continuous Model

Plan, Elodie L; Elshoff, Jan-Peer; Stockis, Armel; Sargentini-Maier, Laura et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 820-828, 2012

• DOI för Likert Pain Scores Modeling: A Markov Integer Model and an Autoregressive Continuous Model

Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment

Ahn, Jae Eun; Plan, Elodie L; Karlsson, Mats O; Miller, Raymond

Ingår i Journal of clinical pharmacology, s. 880-892, 2012

• DOI för Modeling longitudinal daily seizure frequency data from pregabalin add-on treatment

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Svensson, Elin; van der Walt, Jan-Stefan; Barnes, Karen I.; Cohen, Karen et al.

Ingår i British Journal of Clinical Pharmacology, s. 465-476, 2012

• DOI för Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

Zhang, Chao; Denti, Paolo; van der Walt, Jan-Stefan; Ren, Yuan et al.

Ingår i Therapeutic Drug Monitoring, s. 481-484, 2012

• DOI för Population Pharmacokinetic Model for Adherence Evaluation Using Lamivudine Concentration Monitoring

Modeling of red blood cell life-spans in hematologically normal populations

Lledo-Garcia, Rocio; Kalicki, Robert M.; Uehlinger, Dominik E.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 453-462, 2012

• DOI för Modeling of red blood cell life-spans in hematologically normal populations

Letter to the editor regarding: "A reduction in between subject variability is not mandatory for selecting a new covariate"

Karlsson, Mats O; Bergstrand, Martin

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 725-726, 2012

• DOI för Letter to the editor regarding: "A reduction in between subject variability is not mandatory for selecting a new covariate"

Standard Error of Empirical Bayes Estimate in NONMEM (R) VI

Kang, Dongwoo; Bae, Kyun-Seop; Houk, Brett E.; Savic, Radojka M. et al.

Ingår i Korean Journal of Physiology & Pharmacology, s. 97-106, 2012

• DOI för Standard Error of Empirical Bayes Estimate in NONMEM (R) VI

Performance of three estimation methods in repeated time-to-event modeling

Karlsson, Kristin E.; Plan, Elodie L.; Karlsson, Mats O.

Ingår i AAPS Journal, s. 83-91, 2011

• DOI för Performance of three estimation methods in repeated time-to-event modeling

A Fast Method for Testing Covariates in Population PK/PD Models

Khandelwal, Akash; Harling, Kajsa; Jonsson, Niclas E.; Hooker, Andrew C. et al.

Ingår i AAPS Journal, s. 464-472, 2011

• DOI för A Fast Method for Testing Covariates in Population PK/PD Models

Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance

Wallin, Johan E; Bergstrand, Martin; Wilczek, Henryk E; Nydert, Per S et al.

Ingår i Therapeutic Drug Monitoring, s. 663-672, 2011

• DOI för Population pharmacokinetics of tacrolimus in pediatric liver transplantation: early posttransplantation clearance

A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Westin, Jerker; Nyholm, Dag; Pålhagen, Sven; Willows, Thomas et al.

Ingår i Clinical neuropharmacology, s. 61-65, 2011

• DOI för A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion

Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.

Trame, Mirjam N; Bergstrand, Martin; Karlsson, Mats O; Boos, Joachim et al.

Ingår i Clinical Cancer Research, s. 6867-6877, 2011

• DOI för Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children.

Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models

Baverel, Paul G.; Savic, Radojka M.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 63-82, 2011

• DOI för Two bootstrapping routines for obtaining imprecision estimates for nonparametric parameter distributions in nonlinear mixed effects models

Modeling sleep data for a new drug in development using Markov mixed-effects models

Kjellsson, Maria C.; Ouellet, Daniele; Corrigan, Brian; Karlsson, Mats O.

Ingår i Pharmaceutical research, s. 2610-2627, 2011

• DOI för Modeling sleep data for a new drug in development using Markov mixed-effects models

Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes

Jauslin, Petra; Frey, Nicolas; Karlsson, Mats

Ingår i Journal of clinical pharmacology, s. 153-164, 2011

• DOI för Modeling of 24-Hour Glucose and Insulin Profiles of Patients With Type 2 Diabetes

Transient Lower Esophageal Sphincter Relaxations PKPD Modeling: Count Model and Repeated Time-To-Event Model

Plan, Elodie L; Ma, Guangli; Någård, Mats; Jensen, Jörgen et al.

Ingår i Journal of Pharmacology and Experimental Therapeutics, 2011

• DOI för Transient Lower Esophageal Sphincter Relaxations PKPD Modeling: Count Model and Repeated Time-To-Event Model

A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma

Johansson, Åsa M.; Hill, Nicola; Perisoglou, Martha; Whelan, Jeremy et al.

Ingår i Therapeutic Drug Monitoring, s. 711-718, 2011

• DOI för A Population Pharmacokinetic/Pharmacodynamic Model of Methotrexate and Mucositis Scores in Osteosarcoma

Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales

Karlsson, Kristin E.; Wilkins, Justin J.; Jonsson, Fredrik; Zingmark, Per-Henrik et al.

Ingår i AAPS Journal, s. 683-691, 2010

• DOI för Modeling Disease Progression in Acute Stroke Using Clinical Assessment Scales

Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus

Wilmshurst, Jo M; van der Walt, Jan-Stefan; Ackermann, Sally; Karlsson, Mats O et al.

Ingår i Journal of Paediatrics and Child Health, s. 17-22, 2010

• DOI för Rescue therapy with high-dose oral phenobarbitone loading for refractory status epilepticus

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

Keizer, Ron J.; Gupta, Anubha; Mac Gillavry, Melvin R.; Jansen, Mendel et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 347-363, 2010

• DOI för A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis

Gupta, Pankaj; Friberg, Lena E; Karlsson, Mats O; Krishnaswami, Sriram et al.

Ingår i Journal of clinical pharmacology, s. 679-687, 2010

• DOI för A Semi-Mechanistic Model of CP-690,550-Induced Reduction in Neutrophil Counts in Patients With Rheumatoid Arthritis

An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers

Silber, Hanna E.; Frey, Nicolas; Karlsson, Mats O.

Ingår i Journal of clinical pharmacology, s. 246-256, 2010

• DOI för An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers
• Ladda ner fulltext (pdf) av An integrated glucose-insulin model to describe oral glucose tolerance test data in healthy volunteers

Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Hansson, Emma K.; Wallin, Johan; Lindman, Henrik; Sandström, Marie et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 839-848, 2010

• DOI för Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression
• Ladda ner fulltext (pdf) av Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression

Approaches to simultaneous analysis of frequency and severity of symptoms

Plan, Elodie L.; Karlsson, Kristin E.; Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, s. 255-259, 2010

• DOI för Approaches to simultaneous analysis of frequency and severity of symptoms

A two-compartment effect site model describes the bispectral index after different rates of propofol infusion

Björnsson, Marcus A.; Norberg, Ake; Kalman, Sigridur; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 243-255, 2010

• DOI för A two-compartment effect site model describes the bispectral index after different rates of propofol infusion

Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

Zandvliet, Anthe S.; Karlsson, Mats O.; Schellens, Jan H. M.; Copalu, William et al.

Ingår i Investigational new drugs, s. 61-75, 2010

• DOI för Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents

Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism

Fanta, Samuel; Jönsson, Siv; Karlsson, Mats O.; Niemi, Mikko et al.

Ingår i Journal of clinical pharmacology, s. 581-597, 2010

• DOI för Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect of NR1I2 Polymorphism

Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin

Ma, Guangli; Friberg, Lena E.; Movin-Osswald, Gunilla; Karlsson, Mats O.

Ingår i British Journal of Clinical Pharmacology, s. 815-824, 2010

• DOI för Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin

Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Ernest, C. Steven; Hooker, Andrew C.; Karlsson, Mats O.

Ingår i Pharmaceutical research, s. 866-877, 2010

• DOI för Methodological Comparison of In Vitro Binding Parameter Estimation: Sequential vs. Simultaneous Non-linear Regression

Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients

Bizzotto, Roberto; Zamuner, Stefano; De Nicolao, Giuseppe; Karlsson, Mats O. et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 137-155, 2010

• DOI för Multinomial logistic estimation of Markov-chain models for modeling sleep architecture in primary insomnia patients

Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach

Keizer, R. J.; Gupta, A.; Karlsson, M. O.; Wanders, J. et al.

Ingår i European Journal of Cancer Supplements, s. 144-144, 2010

• DOI för Evaluation of management of hypertension in response to the receptor tyrosine kinase inhibitor, E7080: a modeling and simulation approach

A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes

Ribbing, Jakob; Hamrén, Bengt; Svensson, Maria K.; Karlsson, Mats O.

Ingår i Journal of clinical pharmacology, s. 861-872, 2010

• DOI för A Model for Glucose, Insulin, and Beta-Cell Dynamics in Subjects With Insulin Resistance and Patients With Type 2 Diabetes

Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM

Petersson, Klas J. F.; Friberg, Lena E.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 493-506, 2010

• DOI för Transforming parts of a differential equations system to difference equations as a method for run-time savings in NONMEM

Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics

Steimer, Jean-Louis; Dahl, Svein G.; De Alwis, Dinesh P.; Gundert-Remy, Ursula et al.

Ingår i European Journal of Cancer, s. 21-32, 2010

• DOI för Modelling the genesis and treatment of cancer: the potential role of physiologically based pharmacodynamics

Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making

Karlsson, Kristin C.; Savić, Radojka M.; Hooker, Andrew C.; Karlsson, Mats O

Ingår i AAPS Journal, s. 148-154, 2009

• DOI för Modeling subpopulations with the $MIXTURE subroutine in NONMEM: finding the individual probability of belonging to a subpopulation for the use in model analysis and improved decision making

Handling data below the limit of quantification in mixed effect models.

Bergstrand, Martin; Karlsson, Mats O.

Ingår i AAPS Journal, s. 371-380, 2009

• DOI för Handling data below the limit of quantification in mixed effect models.

Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

Savic, Radojka; Karlsson, Mats

Ingår i AAPS Journal, s. 558-569, 2009

• DOI för Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions

Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions

Savic, Radojka; Karlsson, Mats

Ingår i AAPS Journal, s. 615-627, 2009

• DOI för Evaluation of an Extended Grid Method for Estimation Using Nonparametric Distributions

Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials

Lledó-García, R.; Hennig, S.; Karlsson, M. O.

Ingår i Clinical Pharmacology and Therapeutics, s. 62-69, 2009

• DOI för Comparison of dose-finding designs for narrow-therapeutic-index drugs: concentration-controlled vs. dose-controlled trials

The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials

Lledó-García, R.; Hennig, S.; Karlsson, M. O.

Ingår i Clinical Pharmacology and Therapeutics, s. 70-76, 2009

• DOI för The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials

Simultaneous optimal experimental design on dose and sample times

Nyberg, Joakim; Karlsson, Mats O.; Hooker, Andrew C.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 125-145, 2009

• DOI för Simultaneous optimal experimental design on dose and sample times

Trial treatment length optimization with an emphasis on disease progression studies

Hennig, Stefanie; Nyberg, Joakim; Hooker, Andrew C; Karlsson, Mats O

Ingår i Journal of clinical pharmacology, s. 323-335, 2009

• DOI för Trial treatment length optimization with an emphasis on disease progression studies

Performance in population models for count data, part I: maximum likelihood approximations.

Plan, Elodie L.; Maloney, Alan; Trocóniz, Iñaki F.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 353-366, 2009

• DOI för Performance in population models for count data, part I: maximum likelihood approximations.

An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

Friberg, L. E.; Vermeulen, A. M.; Petersson, K. J. F.; Karlsson, M. O.

Ingår i Clinical Pharmacology and Therapeutics, s. 409-417, 2009

• DOI för An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment

A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis

Lacroix, B. D.; Lovern, M R; Stockis, A; Sargentini-Maier, M L et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 387-395, 2009

• DOI för A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis

The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

Lannergård, Anders; Viberg, Anders; Cars, Otto; Karlsson, Mats O. et al.

Ingår i Scandinavian Journal of Infectious Diseases, s. 663-671, 2009

• DOI för The time course of body temperature, serum amyloid A protein, C-reactive protein and interleukin-6 in patients with bacterial infection during the initial 3 days of antibiotic therapy

A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis

Lacroix, Brigitte; Karlsson, Mats; Friberg, Lena

Ingår i Clinical Pharmacology and Therapeutics, s. 387-395, 2009

• DOI för A Pharmacodynamic Markov Mixed-Effects Model for Determining the Effect of Exposure to Certolizumab Pegol on the ACR20 Score in Patients With Rheumatoid Arthritis

Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Friberg, Lena; de Greef, R.; Kerbusch, T.; Karlsson, Mats

Ingår i Clinical Pharmacology and Therapeutics, s. 84-91, 2009

• DOI för Modeling and Simulation of the Time Course of Asenapine Exposure Response and Dropout Patterns in Acute Schizophrenia

Evaluation of the Nonparametric Estimation Method in NONMEM VI

Savic, Radojka M.; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i European Journal of Pharmaceutical Sciences, s. 27-35, 2009

• DOI för Evaluation of the Nonparametric Estimation Method in NONMEM VI

Semiparametric Distributions with Estimated Shape Parameters

Petersson, Klas; Hanze, Eva; Savic, Radojka; Karlsson, Mats

Ingår i Pharmaceutical research, s. 2174-2185, 2009

• DOI för Semiparametric Distributions with Estimated Shape Parameters

The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion

Silber, Hanna E; Kjellsson, Maria C; Karlsson, Mats O

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 81-99, 2009

• DOI för The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion

Evaluation of the Nonparametric Estimation Method in NONMEM VI: Application to Real Data

Baverel, Paul; Savic, Radojka; Wilkins, Justin; Karlsson, Mats

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 297-315, 2009

• DOI för Evaluation of the Nonparametric Estimation Method in NONMEM VI: Application to Real Data

A tool for neutrophil guided dose adaptation in chemotherapy

Wallin, Johan E.; Friberg, Lena E.; Karlsson, Mats O.

Ingår i Computer Methods and Programs in Biomedicine, s. 283-291, 2009

• DOI för A tool for neutrophil guided dose adaptation in chemotherapy
• Ladda ner fulltext (pdf) av A tool for neutrophil guided dose adaptation in chemotherapy

Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

Silber, Hanna E.; Nyberg, Joakim; Hooker, Andrew C.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 281-295, 2009

• DOI för Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design
• Ladda ner fulltext (pdf) av Optimization of the intravenous glucose tolerance test in T2DM patients using optimal experimental design

Modelling overdispersion and Markovian features in count data.

Trocóniz, Iñaki F; Plan, Elodie L.; Miller, Raymond; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 461-477, 2009

• DOI för Modelling overdispersion and Markovian features in count data.

A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling

Karlsson, Kristin C.; van de Schootbrugge, Margunn; Eriksen, Heidi Oien; Moberg, Enrica Ratti et al.

Ingår i Therapeutic Drug Monitoring, s. 86-94, 2009

• DOI för A population pharmacokinetic model of gabapentin developed in nonparametric adaptive grid and nonlinear mixed effects modeling

Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics

Bergstrand, Martin; Söderlind, E.; Weitschies, W.; Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, s. 77-83, 2009

• DOI för Mechanistic modeling of a magnetic marker monitoring study linking gastrointestinal tablet transit, in vivo drug release, and pharmacokinetics

Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

Karlsson, Mats O; Lutsar, Irja; Milligan, Peter A

Ingår i Antimicrobial Agents and Chemotherapy, s. 935-944, 2009

• DOI för Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies

Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin

Magnusson, M O; Dahl, M-L; Cederberg, J; Karlsson, M O et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 52-62, 2008

• DOI för Pharmacodynamics of carbamazepine-mediated induction of CYP3A4, CYP1A2, and Pgp as assessed by probe substrates midazolam, caffeine, and digoxin

Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

Hooker, Andrew C; Ten Tije, A J; Carducci, M A; Weber, J et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 111-118, 2008

• DOI för Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements

Approaches to handling pharmacodynamic baseline responses

Dansirikul, Chantaratsamon; Silber, Hanna E; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 269-283, 2008

• DOI för Approaches to handling pharmacodynamic baseline responses

The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

Tunblad, Karin; Lindbom, Lars; McFadyen, Lynn; Jonsson, E. Niclas et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 503-526, 2008

• DOI för The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharmacokinetic data

Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption

Wilkins, Justin J.; Savic, Radojka M.; Karlsson, Mats O.; Langdon, Grant et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 2138-2148, 2008

• DOI för Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients Including a Semi-mechanistic Model to Describe Variable Absorption

A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens

Elsherbiny, Doaa A.; Asimus, Sara A.; Karlsson, Mats O.; Ashton, Michael et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 203-217, 2008

• DOI för A model based assessment of the CYP2B6 and CYP2C19 inductive properties by artemisinin antimalarials: implications for combination regimens

Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function: evidence of interconversion

Hamrén, Bengt; Ericsson, Hans; Samuelsson, Ola; Karlsson, Mats O.

Ingår i British Journal of Clinical Pharmacology, s. 855-863, 2008

• DOI för Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function: evidence of interconversion

Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

Hamrén, Bengt; Björk, Elisabeth; Sunzel, Maria; Karlsson, Mats O

Ingår i Clinical Pharmacology and Therapeutics, s. 228-235, 2008

• DOI för Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment

Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data

Kjellsson, Maria C.; Zingmark, Per-Henrik; Jonsson, E. Niclas; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 483-501, 2008

• DOI för Comparison of proportional odds and differential odds models for mixed-effects analysis of categorical data

Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues

Tornøe, Christoffer W.; Agersø, Henrik; Senderovitz, Thomas; Nielsen, Henrik A. et al.

Ingår i British Journal of Clinical Pharmacology, s. 648-664, 2007

• DOI för Population pharmacokinetic/pharmacodynamic (PK/PD) modelling of the hypothalamic-pituitary-gonadal axis following treatment with GnRH analogues

Randomized exposure-controlled trials: Impact of randomization and analysis strategies

Karlsson, Kristin E.; Grahnén, Anders; Karlsson, Mats O.; Jonsson, E. Niclas

Ingår i British Journal of Clinical Pharmacology, s. 266-277, 2007

• DOI för Randomized exposure-controlled trials: Impact of randomization and analysis strategies

Implementation of a Transit Compartment Model for Describing Drug Absorption in Pharmacokinetic Studies

Savic, Radojka M.; Jonker, Daniël M.; Kerbusch, Thomas; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 711-726, 2007

• DOI för Implementation of a Transit Compartment Model for Describing Drug Absorption in Pharmacokinetic Studies

Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

Nielsen, Elisabet I.; Viberg, Anders; Löwdin, Elisabeth; Cars, Otto et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 128-136, 2007

• DOI för Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

Diagnosing Model Diagnostics

Karlsson, Mats; Savic, Radojka

Ingår i Clinical Pharmacology and Therapeutics, s. 17-20, 2007

• DOI för Diagnosing Model Diagnostics

Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

van Erp, Nielka P; Gelderblom, Hans; Karlsson, Mats O; Li, Jing et al.

Ingår i Clinical Cancer Research, s. 7394-7400, 2007

• DOI för Influence of CYP3A4 Inhibition on the Steady-State Pharmacokinetics of Imatinib

An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics

Jauslin, Petra M; Silber, Hanna E; Frey, Nicolas; Gieschke, Ronald et al.

Ingår i Journal of clinical pharmacology, s. 1244-1255, 2007

• DOI för An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics

Optimal adaptive design in clinical drug development: a simulation example

Maloney, Alan; Karlsson, Mats O; Simonsson, Ulrika S H

Ingår i Journal of clinical pharmacology, s. 1231-1243, 2007

• DOI för Optimal adaptive design in clinical drug development: a simulation example

An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations

Silber, Hanna E; Jauslin, Petra M; Frey, Nicolas; Gieschke, Ronald et al.

Ingår i Journal of clinical pharmacology, s. 1159-1171, 2007

• DOI för An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations

Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates

Fanta, Samuel; Jönsson, Siv; Backman, Janne T; Karlsson, Mats O et al.

Ingår i British Journal of Clinical Pharmacology, s. 772-784, 2007

• DOI för Developmental pharmacokinetics of ciclosporin: a population pharmacokinetic study in paediatric renal transplant candidates

Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method

Hooker, Andrew C.; Staatz, Christine E; Karlsson, Mats O

Ingår i Pharmaceutical research, s. 2187-2197, 2007

• DOI för Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method

Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum

Holford, N; Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, s. 103-105, 2007

• DOI för Time for quantitative clinical pharmacology: a proposal for a pharmacometrics curriculum

An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers

Lönnebo, Anna; Grahnén, Anders; Karlsson, Mats O.

Ingår i British Journal of Clinical Pharmacology, s. 125-132, 2007

• DOI för An integrated model for the effect of budesonide on ACTH and cortisol in healthy volunteers

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Langdon, Grant; Gueorguieva, Ivelina; Aarons, Leon; Karlsson, Mats

Ingår i European Journal of Clinical Pharmacology, s. 485-498, 2007

• DOI för Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG

Joerger, Markus; Huitema, Alwin D R; Richel, Dick J; Dittrich, Christian et al.

Ingår i Clinical Pharmacokinetics, s. 1051-1068, 2007

Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Overgaard, Rune V.; Karlsson, Mats; Ingwersen, Steen H.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 559-574, 2007

• DOI för Pharmacodynamic model of interleukin-21 effects on red blood cells in cynomolgus monkeys.

Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Joerger, Markus; Huitema, Alwin D. R.; Richel, Dick J.; Dittrich, Christian et al.

Ingår i Clinical Cancer Research, s. 6410-6418, 2007

• DOI för Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.

Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Quartino, Angelica; Karlsson, Mats O.; Freijs, Agneta; Jonsson, Niclas et al.

Ingår i Journal of clinical pharmacology, s. 1014-1021, 2007

• DOI för Modeling of in vitro drug activity and prediction of clinical outcome in acute myeloid leukemia

Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults

Østerberg, Ole; Savic, Radojka; Karlsson, Mats; Simonsson, Ulrika et al.

Ingår i Journal of clinical pharmacology, s. 1204-1211, 2006

• DOI för Pharmacokinetics of Desmopressin Administrated as an Oral Lyophilisate Dosage Form in Children With Primary Nocturnal Enuresis and Healthy Adults

Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs

Kloft, Charlotte; Wallin, Johan; Henningsson, Anja; Chatelut, Etienne et al.

Ingår i Clinical Cancer Research, s. 5481-5490, 2006

• DOI för Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs
• Ladda ner fulltext (pdf) av Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs

A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Viberg, Anders; Lannergård, Anders; Larsson, Anders; Cars, Otto et al.

Ingår i British Journal of Clinical Pharmacology, s. 297-303, 2006

• DOI för A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function

Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog

Äbelö, Angela; Andersson, Magdalena; Holmberg, Ann Aurell; Karlsson, Mats O.

Ingår i European Journal of Pharmaceutical Sciences, s. 91-101, 2006

• DOI för Application of a combined effect compartment and binding model for gastric acid inhibition of AR-HO47108: a potassium competitive acid blocker, and its active metabolite AR-HO47116 in the dog

Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy

Bååthe, Sofie; Hamrén, Bengt; Karlsson, Mats O.; Wollbratt, Maria et al.

Ingår i Clinical Pharmacokinetics, s. 803-819, 2006

• DOI för Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat

Magnusson, Mats O.; Karlsson, Mats O.; Sandström, Rikard

Ingår i Pharmacological Research, s. 521-532, 2006

• DOI för A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat

CHS 828 kill tumour cells by inhibiting the nuclear factor-kappa B translocation but unlikely through down-regulation of proteasome

Hassan, Saadia B.; Lövborg, Henrik; Lindhagen, Elin; Karlsson, Mats O. et al.

Ingår i Anticancer Research, s. 4431-4436, 2006

CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

Li, Jing; Karlsson, Mats O.; Brahmer, Julie; Spitz, Avery et al.

Ingår i Journal of the National Cancer Institute, s. 1714-1723, 2006

• DOI för CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors

A mechanism-based integrated pharmacokinetic enzyme model describing the time course and magnitude of phenobarbital-mediated enzyme induction in the rat.

Magnusson, Mats O; Karlsson, Mats O; Sandström, Rikard

Ingår i Pharm Res, s. 521-32, 2006

Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.

Sandström, M; Lindman, H; Nygren, P; Johansson, M et al.

Ingår i Cancer Chemother Pharmacol, s. 143-56, 2006

Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy.

Latz, Jane E; Rusthoven, James J; Karlsson, Mats O; Ghosh, Atalanta et al.

Ingår i Cancer Chemother Pharmacol, s. 427-35, 2006

A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy.

Latz, Jane E; Karlsson, Mats O; Rusthoven, James J; Ghosh, Atalanta et al.

Ingår i Cancer Chemother Pharmacol, s. 412-26, 2006

Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Zingmark, Per-Henrik; Kågedal, Matts; Karlsson, Mats O

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 261-281, 2005

• DOI för Modelling a spontaneously reported side effect by use of a Markov mixed-effects model.

Pharmacokinetic-Pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model

Friberg, Lena; Hassan, Saadia Bashir; Lindhagen, Elin; Larsson, Rolf et al.

Ingår i European Journal of Pharmaceutical Sciences, s. 163-173, 2005

• DOI för Pharmacokinetic-Pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug

Jönsson, Siv; Karlsson, Mats O.

Ingår i European Journal of Pharmaceutical Sciences, s. 123-132, 2005

• DOI för Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug

Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke

Jönsson, Siv; Cheng, Yi-Fang; Edenius, Charlotte; Lees, Kennedy R. et al.

Ingår i Clinical Pharmacokinetics, s. 863-878, 2005

Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer

Sandström, Marie; Lindman, Henrik; Nygren, Peter; Lidbrink, Elisabet et al.

Ingår i Journal of Clinical Oncology, s. 413-421, 2005

• DOI för Model describing the relations between pharmacokinetics and hematological toxicity of the epirubicin-docetaxel regimen in breast cancer

Pharmacokinetics of ximelagatran and relationship to clinical response in acute vein thrombosis

Cullberg, Marie; Eriksson, Ulf G.; Wåhlander, Karin; Eriksson, Henry et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 279-290, 2005

• DOI för Pharmacokinetics of ximelagatran and relationship to clinical response in acute vein thrombosis

Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo

Hassan, Saadia Bashir; Dhar, Sumeer; Sandström, Marie; Arsenau, Dzmitry et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 47-54, 2005

• DOI för Cytotoxic activity of a new paclitaxel formulation, Pacliex, in vitro and in vivo

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.

Henningsson, Anja; Marsh, Sharon; Loos, Walter J; Karlsson, Mats O et al.

Ingår i Clin Cancer Res, s. 8097-104, 2005

Model describing the relationship between pharmacokinetics and hematologic toxicity of the epirubicin-docetaxel regimen in breast cancer patients.

Sandström, M; Lindman, Henrik; Nygren, Peter; Lidbrink, E et al.

Ingår i J Clin Oncol, s. 413-21, 2005

A semiphysiological pharmacokinetic model for artemisinin in healthy subjects incorporating autoinduction of metabolism and saturable first-pass hepatic extraction.

Gordi, Toufigh; Xie, Rujia; Huong, Nguyen V; Huong, Dinh X et al.

Ingår i Br J Clin Pharmacol, s. 189-98, 2005

Application of population pharmacokinetics to cladribine.

Lindemalm, Synnöve; Savic, Radojka M; Karlsson, Mats O; Juliusson, Gunnar et al.

Ingår i BMC Pharmacol, s. 4, 2005

Estimation of dosing strategies aiming at maximizing utility or responder probability, using oxybutynin as an example drug.

Jönsson, Siv; Karlsson, Mats O

Ingår i Eur J Pharm Sci, s. 123-32, 2005

Pharmacokinetic-pharmacodynamic modelling of the schedule-dependent effect of the anti-cancer agent CHS 828 in a rat hollow fibre model.

Friberg, Lena E; Hassan, Saadia B; Lindhagen, Elin; Larsson, Rolf et al.

Ingår i Eur J Pharm Sci, s. 163-73, 2005

Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.

van Kesteren, Charlotte; Zandvliet, Anthe S; Karlsson, Mats O; Mathôt, Ron A A et al.

Ingår i Invest New Drugs, s. 225-34, 2005

Pharmacokinetics of ximelagatran and relationship to clinical response in acute deep vein thrombosis.

Cullberg, Marie; Eriksson, Ulf G; Wåhlander, Karin; Eriksson, Henry et al.

Ingår i Clin Pharmacol Ther, s. 279-90, 2005

Population pharmacokinetic modelling and estimation of dosing strategy for NXY-059, a nitrone being developed for stroke.

Jönsson, Siv; Cheng, Yi-Fang; Edenius, Charlotte; Lees, Kennedy R et al.

Ingår i Clin Pharmacokinet, s. 863-78, 2005

Pharmacokinetic/pharmacodynamic modelling in oncological drug development.

Karlsson, Mats O; Anehall, Therese; Friberg, Lena E; Henningsson, Anja et al.

Ingår i Basic Clin Pharmacol Toxicol, s. 206-11, 2005

The back-step method: method for obtaining unbiased population parameter estimates for ordered categorical data

Kjellsson, Maria C.; Jönsson, Siv; Karlsson, Mats O.

Ingår i AAPS Journal, s. 13-22, 2004

• DOI för The back-step method: method for obtaining unbiased population parameter estimates for ordered categorical data

Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED

Jönsson, Siv; Kjellsson, Maria C.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 299-320, 2004

• DOI för Estimating bias in population parameters for some models for repeated measures ordinal data using NONMEM or NLMIXED

Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

Zingmark, Per-Henrik; Edenius, Charlotte; Karlsson, Mats O.

Ingår i British Journal of Clinical Pharmacology, s. 378-389, 2004

• DOI för Pharmacokinetic/pharmacodynamic models for the depletion of Vβ5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Kerbusch, Thomas; Wählby, Ulrika; Milligan, Peter A; Karlsson, Mats O

Ingår i British Journal of Clinical Pharmacology, s. 639-652, 2003

• DOI för Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Zingmark, Per-Henrik; Ekblom, Marianne; Odergren, Tomas; Ashwood, Tim et al.

Ingår i British Journal of Clinical Pharmacology, s. 173-183, 2003

• DOI för Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Mechanistic models for myelosuppression

Friberg, Lena E; Karlsson, Mats O

Ingår i Investigational new drugs, s. 183-194, 2003

• DOI för Mechanistic models for myelosuppression

Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia

Lindemalm, Synnove; Liliemark, Jan; Gruber, Astrid; Eriksson, Staffan et al.

Ingår i Haematologica, s. 324-332, 2003

Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial

Hornestam, Björn; Jerling, Markus; Karlsson, Mats O; Held, Peter

Ingår i European Journal of Clinical Pharmacology, s. 747-755, 2003

• DOI för Intravenously administered digoxin in patients with acute atrial fibrillation: a population pharmacokinetic/pharmacodynamic analysis based on the Digitalis in Acute Atrial Fibrillation trial

Population pharmacokinetics of levosimendan in patients with congestive heart failure

Jonsson, E Niclas; Antila, Saila; McFadyen, Lynn; Lehtonen, Lasse et al.

Ingår i British Journal of Clinical Pharmacology, s. 544-551, 2003

• DOI för Population pharmacokinetics of levosimendan in patients with congestive heart failure

A rational approach for selection of optimal covariate-based dosing strategies

Jönsson, Siv; Karlsson, Mats O

Ingår i Clinical Pharmacology and Therapeutics, s. 7-19, 2003

• DOI för A rational approach for selection of optimal covariate-based dosing strategies

Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

Henningsson, Anja; Sparreboom, Alex; Sandström, Marie; Freijs, Agneta et al.

Ingår i European Journal of Cancer, s. 1105-1114, 2003

• DOI för Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients

Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

Zingmark, Per-Henrik; Ekblom, Marianne; Odergren, Tomas; Ashwood, Tim et al.

Ingår i British Journal of Clinical Pharmacology, s. 173-183, 2003

• DOI för Population pharmacokinetics of clomethiazole and its effect on the natural course of sedation in acute stroke patients

The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

Agerso¸, Henrik; Koechling, Wolfgang; Knutsson, Magnus; Hjortkjaer, Rolf et al.

Ingår i European Journal of Pharmaceutical Sciences, s. 335-340, 2003

• DOI för The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after s.c. administration to beagle dogs.

A rational approach for selection of optimal covariate-based dosing strategies

Jönsson, Siv; Karlsson, Mats O.

Ingår i Clinical Pharmacology and Therapeutics, s. 7-19, 2003

• DOI för A rational approach for selection of optimal covariate-based dosing strategies

Irinotecan pathway genotype analysis to predict pharmacokinetics

Mathijssen, Ron H J; Marsh, Sharon; Karlsson, Mats O; Xie, Rujia et al.

Ingår i Clinical Cancer Research, s. 3246-3253, 2003

Variable Expression of CYP and Pgp Genes in the Human Small Intestine

Lindell, Monica; Karlsson, Mats O.; Lennernäs, Hans; Påhlman, Lars et al.

Ingår i European Journal of Clinical Investigation, s. 493-499, 2003

• DOI för Variable Expression of CYP and Pgp Genes in the Human Small Intestine

Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

Xie, Rujia; Mathijssen, Ron H J; Sparreboom, Alex; Verweij, Jaap et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 265-275, 2002

• DOI för Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea

Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole

Äbelö, Angela; Holstein, Björn; Eriksson, Ulf G.; Gabrielsson, Johan et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 365-382, 2002

• DOI för Gastric acid secretion in the dog: a mechanism-based pharmacodynamic model for histamine stimulation and irreversible inhibition by omeprazole

Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

Friberg, Lena E.; Henningsson, Anja; Maas, Hugo; Nguyen, Laurent et al.

Ingår i Journal of Clinical Oncology, s. 4713-4721, 2002

• DOI för Model of Chemotherapy-Induced Myelosuppression With Parameter Consistency Across Drugs

A Phase I Study of CHS 828 in Patients with Solid Tumor Malignancy

Hovstadius, Peter; Larsson, Rolf; Lindhagen, Elin; Skov, Torsten et al.

Ingår i Clinical Cancer Research, s. 2843-2850, 2002

Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

Friberg, Lena E.; Henningsson, Anja; Maas, Hugo; Nguyen, Laurent et al.

Ingår i Journal of Clinical Oncology, s. 4713-4721, 2002

• DOI för Model of chemotherapy-induced myelosuppression with parameter consistency across drugs

Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.

Svensson, Ulrika S H; Alin, Hassan; Karlsson, Mats O; Bergqvist, Yngve et al.

Ingår i European Journal of Clinical Pharmacology, s. 339-351, 2002

• DOI för Population pharmacokinetic and pharmacodynamic modelling of artemisinin and mefloquine enantiomers in patients with falciparum malaria.

Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Wählby, Ulrika; Jonsson, E Niclas; Karlsson, Mats O

Ingår i AAPS PharmSci, 2002

Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease

Cullberg, Marie; Eriksson, Ulf G.; Larsson, Marita; Karlsson, Mats O.

Ingår i British Journal of Clinical Pharmacology, s. 71-79, 2001

• DOI för Population modelling of the effect of inogatran, at thrombin inhibitor, on ex vivo coagulation time (APTT) in healthy subjects and patients with coronary artery disease

Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man

Äbelö, Angela; Gabrielsson, Johan; Holstein, Björn; Eriksson, Ulf G et al.

Ingår i European Journal of Pharmaceutical Sciences, s. 339-346, 2001

• DOI för Pharmacodynamic modelling of reversible gastric acid pump inhibition in dog and man

A hollow fiber model for in vitro studies of cytotoxic compounds: Activity of the cyanoguanidine CHS 828

Hassan, Saadia Bashir; de la Torre, Manuel; Nygren, Peter; Karlsson, Mats O. et al.

Ingår i Anti-Cancer Drugs, s. 33-42, 2001

Model for time dependency of the cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action

Hassan, Saadia Bashir; Jonsson, Elin; Larsson, Rolf; Karlsson, Mats O.

Ingår i Journal of Pharmacology and Experimental Therapeutics, s. 1140-1147, 2001

Mechanism-based pharmacokinetic model for paclitaxel

Henningsson, Anja; Karlsson, Mats O.; Viganò, Lucia; Gianni, Luca et al.

Ingår i Journal of Clinical Oncology, s. 4065-4073, 2001

Haematological toxicity following different dosing schedules of 5-fluorouracil and epirubicin in rats

Simonsen, Lena E.; Wählby, Ulrika; Sandström, Marie; Freijs, Agneta et al.

Ingår i Anticancer Research, s. 1519-1525, 2000

Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats

Jonsson, Elin; Friberg, Lena E.; Karlsson, Mats O.; Hassan, Saadia Bashir et al.

Ingår i Cancer Chemotherapy and Pharmacology, s. 493-500, 2000

• DOI för Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats

A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog

Äbelö, Angela; Eriksson, Ulf G; Karlsson, Mats O.; Larsson, Håkan et al.

Ingår i Journal of Pharmacology and Experimental Therapeutics, s. 662-669, 2000

Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice.

Sundberg, J; Jönsson, S; Karlsson, M O; Oskarsson, A

Ingår i Toxicology and Applied Pharmacology, s. 160-9, 1999

• DOI för Lactational exposure and neonatal kinetics of methylmercury and inorganic mercury in mice.

The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

Olsson Gisleskog, Per; Hermann, David; Hammarlund-Udenaes, Margareta; Karlsson, Mats O

Ingår i British Journal of Clinical Pharmacology, s. 53-58, 1999

• DOI för The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination

Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice.

Sundberg, J; Jönsson, S; Karlsson, M O; Hallén, I P et al.

Ingår i Toxicology and Applied Pharmacology, s. 319-29, 1998

• DOI för Kinetics of methylmercury and inorganic mercury in lactating and nonlactating mice.

Toxicokinetics of lead in lactating and nonlactating mice.

Hallén, I P; Jönsson, Siv; Karlsson, M O; Oskarsson, A

Ingår i Toxicology and Applied Pharmacology, s. 342-7, 1996

• DOI för Toxicokinetics of lead in lactating and nonlactating mice.

Kinetic observations in neonatal mice exposed to lead via milk.

Palminger Hallén, I; Jönsson, S; Karlsson, M O; Oskarsson, A

Ingår i Toxicology and Applied Pharmacology, s. 13-8, 1996

Utility of ecarin clotting time, an ex vivo coagulation test, for pharmacokinetic analysis of the direct thrombin inhibitor melagatran

Cullberg, Marie; Wählby, Ulrika; Karlsson, Mats O.; Eriksson, Ulf G.

Population pharmacokinetics of tacrolimus in paediatric liver transplant recipients: a model to describe early post-transplantation apparent clearance

Wallin, Johan; Wilczek, Henryk; Nydert, Per S.; Karlsson, Mats O. et al.

Ingår i American Journal of Transplantation

• Ladda ner fulltext (pdf) av Population pharmacokinetics of tacrolimus in paediatric liver transplant recipients: a model to describe early post-transplantation apparent clearance

Predictive performance of internal and external validation procedures

Baverel, Paul G; Karlsson, Kristin E; Karlsson, Mats O

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients

Abrantes, João; Solms, Alexander; Garmann, Dirk; Nielsen, Elisabet I. et al.

Item Response Theory-Informed Total Score Analysis

Wellhagen, Gustaf J.; Ueckert, Sebastian; Kjellsson, Maria C.; Karlsson, Mats O.

Covariate modeling in pharmacometrics: General points for consideration

Sanghavi, Kinjal; Ribbing, Jakob; Rogers, James A.; Ahmed, Mariam A. et al.

Ingår i CPT, s. 710-728, 2024

• DOI för Covariate modeling in pharmacometrics: General points for consideration
• Ladda ner fulltext (pdf) av Covariate modeling in pharmacometrics: General points for consideration

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Hermann, Robert; Karlsson, Mats O; Novakovic, Ana M.; Terranova, Nadia et al.

Ingår i Clinical Pharmacokinetics, s. 283-297, 2019

• DOI för The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis
• Ladda ner fulltext (pdf) av The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis

Open innovation: Towards sharing of data, models and workflows

Conrado, Daniela J.; Karlsson, Mats O; Romero, Klaus; Sarr, Celine et al.

Ingår i European Journal of Pharmaceutical Sciences, 2017

• DOI för Open innovation: Towards sharing of data, models and workflows

An Integrated Model for the Glucose-Insulin System

Silber, Hanna E.; Jauslin, Petra M.; Frey, Nicolas; Karlsson, Mats O.

Ingår i Basic & Clinical Pharmacology & Toxicology, s. 189-194, 2010

• DOI för An Integrated Model for the Glucose-Insulin System

Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information

Wallin, Johan E.; Friberg, Lena E.; Karlsson, Mats O.

Ingår i Basic & Clinical Pharmacology & Toxicology, s. 234-242, 2010

• DOI för Model-Based Neutrophil-Guided Dose Adaptation in Chemotherapy: Evaluation of Predicted Outcome with Different Types and Amounts of Information

Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework

Dahl, Svein G.; Aarons, Leon; Gundert-Remy, Ursula; Karlsson, Mats O. et al.

Ingår i Basic & Clinical Pharmacology & Toxicology, s. 2-12, 2010

• DOI för Incorporating Physiological and Biochemical Mechanisms into Pharmacokinetic-Pharmacodynamic Models: A Conceptual Framework

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

Eriksson, Ulf G; Mandema, Jaap W; Karlsson, Mats O; Frison, Lars et al.

Ingår i Clinical Pharmacokinetics, s. 687-701, 2003

Factors influencing the choice of optimal individualized dosing strategies targeting a drug concentration or effect

Jönsson, Siv; Matolcsi, Katalin; Mentré, France; Karlsson, Mats O.

2004

Pharmacokinetic-pharmacodynamic modeling of the schedule-dependent effect of CHS 828 in a rat hollow fiber model

Friberg, Lena E.; Hassan, Saadia B.; Jonsson, Elin; Larsson, Rolf et al.

Expression of UDP-Glucuronosyltransferase Genes (UGTs) in Human Duodenum

Lindell, Monica; Karlsson, Mats O.; Påhlman, Lars; Lennernäs, Hans et al.

Application of a combined effect-compartment and binding model for gastric acid inhibition of AR-HO47108, a reversible gastric acid proton pump inhibitor, and its active metabolite AR-HO47116, in the dog

Äbelö, Angela; Holstein, Björn; Andersson, Magdalena; Karlsson, Mats O

Does the novel anticancer agent CHS 828 induces tumor cell death by inhibiting the transcription factor NF-kB translocation through down regulation of the proteasome?

Hassan, Saadia Bashir; Lövborg, Henrik; Lindhagen, Elin; Karlsson, Mats O et al.

Population Pharmacokinetic Model for Cremophor EL

Henningsson, Anja; Sparreboom, Alex; Loos, Walter J.; Verweij, Jaap et al.

Comparing the differential drug effect model to the proportional odds model

Zingmark, Per-Henrik; Kjellsson, Maria C.; Jonsson, E. Niclas; Karlsson, Mats O.

The time course of the biomarkers body temperature, serum amyloid A protein (SAA), C-reactive protein (CRP) and interleukin- (IL) 6 during initial treatment with cefuroxime in patients with bacterial infections

Viberg, Anders; Lannergård, Anders; Cars, Otto; Karlsson, Mats O et al.

Individualization of Cefuroxime Dosage using Pharmacodynamic targets, MIC distributions and Minimization of a Risk Function

Viberg, Anders; Cars, Otto; Karlsson, Mats O; Jönsson, Siv

Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis

Lindbom, Lars; Wilkins, Justin J; Frey, Nicolas; Karlsson, Mats O et al.

Ximelagatran in extended secondary prevention of venous thromboembolism: Pharmacokinetics, pharmacodynamics and relationships to clinical events

Cullberg, Marie; Wåhlander, Karin; Lundström, Torbjörn; Wall, Ulrika et al.

A mechanistic model describing the impact of carbamazepine on the pharmacokinetics of clomethiazole and its metabolite NLA-715

Magnusson, Mats O.; Zingmark, Per-Henrik; Fransson, Bo; Karlsson, Mats O. et al.

Pharmacodynamics of enzyme induction attributable to carbamazepine treatment using midazolam, caffeine and digoxin as probe substrates

Magnusson, Mats O.; Dahl, Marja-Liisa; Cederberg, Jonas; Karlsson, Mats O. et al.

A novel covariate search method intended for PKPD models with nonparametric parameter distributions

Baverel, Paul; Savic, Rada; Marshall, Scott; Karlsson, Mats

Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis

Svensson, Elin M; Rossenu, Stefaan; Karlsson, Mats O

Optimal Design Applied to Hematological Toxicity-Induced Anticancer Treatment

Vong, Camille; Nyberg, Joakim; Karlsson, Mats O.; Friberg, Lena E. et al.

Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects

Ernest II, Charles; Bizzotto, Roberto; DeBrota, David J.; Ni, Lan et al.

• Ladda ner fulltext (pdf) av Multinomial Markov-chain model of sleep architecture in Phase Advanced Subjects

Challenges and potential of optimal design in late phase clinical trials through application in Alzheimer’s disease

Ueckert, Sebastian; Andrew, Marilee A.; Karlsson, Mats; Ito, Kaori et al.

Characterization of Anti-Drug Antibody Dynamics Using a Bivariate Mixed Hidden-Markov Model

Brekkan, Ari; Lledo-Garcia, Rocio; Lacroix, Brigitte; Jönsson, Siv et al.

The influence of second-line immuno-therapies on the survival outcome of first-line non-small cell lung cancer atezolizumab IMpower131 study: An application of multistate modeling

Madathil Krishnan, Sreenath; Friberg, Lena; Zhang, Rong; Mercier, Francois et al.

Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L; Cramer, Yoninah S et al.

Assessment of non-linear mixed effect model-based approaches to test for drug effect using simulated data: type I error and power properties.

Chasseloup, Estelle; Tessier, Adrien; Karlsson, Mats

Extension of individual model averaging assessments to unbalanced designs and dose-response.

Chasseloup, Estelle; Li, Xinyi; Karlsson, Mats

Comparative Analysis of Pharmacoeconomic and Pharmacometric Modeling in the Cost-Effectiveness Evaluation of Sunitinib Therapy with Therapeutic Drug Monitoring for Gastrointestinal Stromal Tumors

Centanni, Maddalena; Nijhuis, Janine; Karlsson, Mats; Friberg, Lena

The metformin intervention (MINT) study – a randomized trial for the treatment of pediatric obesity

Ciba, Iris; Manell, Hannes; Andersson, Kerstin; Aydin, Banu K. et al.